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Abstract 
Globalization has created a dynamic and rapidly changing marketplace. A business must 
move quickly to capitalize on the changing environment. For example, many global 
biotechnology firms are seeking new geographical locations as part of their strategy to 
expand their business. 
 
Korea’s biotechnology reputation and prospects as a potential site for biotech businesses 
is attracting increase attention. The Yeongjong Project is one choice. For the ongoing 
development of Korean bioclusters, this study will demonstrate potential and the 
attractiveness of Korea’s biocluster sites, which may help international biotechnology 
firms relocate and reposition in Korea. 
 
Biotechnology is an umbrella term so this study identifies what the biotechnology and 
biotechnology industry are, as well as its characteristics and risks. 
 
Secondly, the biotechnology market will be analyzed both globally and domestically to 
understand the industry trend. This paper compares successful international bioclusters 
such as Tuas Medical Park in Singapore and University Park at MIT in the U.S, along 
with Korea’s Wonju Medical Valley and Daedeok Techno Valley. This study explains 
different innovations and success factors, and characteristics of each cluster and whether 
the success factors are applicable to the Yeongjong Project. 
 
Finally, this thesis will identify the area and its characteristics suitable for a biocluster 
and propose appropriate product types through market feasibility. 
 
 
 
 
Thesis Supervisor: Brian A. Ciochetti 
Title: Professor of the Practice of Real Estate 
 - 3 - 
 
Acknowledgements 
 
I would like to express my thanks to the MIT faculty members who have assisted me in 
the process of writing this thesis.  I especially want to thank Professor Tony Ciochetti 
for his inspiring and experienced comments, attentive attitude, and logical advice. 
 
I owe special gratitude to Tony Ciochetti for his patience, guidance, and favorable 
support along the way, particularly over the past year in the MSRED program. I would 
also like to thank him for his great speech at my wedding ceremony, despite of his tight 
schedule.  
 
I also want to thank John Infantino, CEO of the Federal Development LLC, and 
Minghuan Du who is charge of the firm’s Asian market. They provided real information 
and keen guidance to approach my thesis close to the real world.  
 
In addition, I cannot express how grateful I am to my father, Dungkyu Choi, and mother, 
Sooah Oh, who supported me while I worked to complete this program at MIT. 
 
Lastly, I am forever indebted to my wife, Jungeun Kim, for her unwavering support and 
love.  Without her support, this thesis would not have been possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 4 - 
 
TABLE OF CONTENTS 
I. INTRODUCTION ....................................................................................................... 7 
II. WHAT IS BIOTECHNOLOGY ............................................................................... 9 
A. Definition ................................................................................................................... 9 
B. A Framework of Biotechnology Industry ................................................................ 10 
1. Classification ........................................................................................................... 10 
2. A Conceptual Model Biotechnology Measurement ................................................ 11 
C. Risks and Characteristics of Biotechnology ............................................................ 13 
1. Risks and Characteristics ........................................................................................ 13 
2. Drug Development Value Chain ............................................................................. 15 
III. BIOTECHNOLOGY MARKET OVERVIEW ................................................... 18 
A. Global Biotechnology Market and Trend ................................................................ 18 
1. Growth ..................................................................................................................... 18 
2. Segmentation of Global Market .............................................................................. 19 
3. Trends ...................................................................................................................... 20 
B. Korean Biotechnology Market and Trend................................................................ 23 
1. Bio-Vision 2016 ...................................................................................................... 23 
2. Trends ...................................................................................................................... 26 
C. Strength, Weakness, Opportunity, and Threat of Korea BT Market ........................ 28 
IV. BIOCLUSTER CASES .......................................................................................... 30 
A. Understanding Biocluster ........................................................................................ 30 
1. Advantage and Disadvantages ................................................................................. 30 
B. Korean Biocluster Cases .......................................................................................... 32 
1. Statistics .................................................................................................................. 32 
2. Case 1, Wonju Medical Techno Valley .................................................................... 34 
3. Case 2, Daedeok Techno Valley .............................................................................. 38 
C. International Biocluster Cases ................................................................................. 42 
1. Case 3, Tuas Biomedical Park in Singapore ........................................................... 42 
2. Case 4, Cambridge Cluster in United Kingdom ...................................................... 46 
3. Case 5, University Park at MIT in the United States .............................................. 51 
V. YEONGJONG PROJECT ....................................................................................... 60 
A. Overview ................................................................................................................. 60 
1. Project ..................................................................................................................... 60 
2. What is IFEZ and Upcoming Projects Surrounding the Candidate Site? ............... 61 
B. Geographical Information, Infrastructure, Tax Zone and Government Support of 
IFEZ .............................................................................................................................. 64 
1. Geographical Information ....................................................................................... 64 
2. Infrastructure of IFEZ; Incheon Airport and Harbor ............................................... 65 
3. Tax Zone .................................................................................................................. 65 
4. Government Support ............................................................................................... 66 
C. Biocluster Business Environment surrounding IFEZ .............................................. 67 
1. Public R&D Centers ................................................................................................ 67 
2. Korea Biotechnology Commercialization Center ................................................... 68 
 - 5 - 
 
3. Incheon Bioindustry Supporting Center, Songdo Techno Park ............................... 68 
4. Clinical Trial Center, Inha University Hospital ....................................................... 69 
5. Celltrion, Biophamaceutical Company ................................................................... 69 
6. TS Corporation R&D Center ................................................................................... 70 
7. Plans in Progress for Biotechnology, Driven by Incheon Government .................. 70 
D. Proposed Business Plan for Pharmaceutical Manufacturing Facilities ................... 72 
1.  Reasons Why Pharmaceutical Manufacturing Facilities is the Optimal Product 
for the Candidate Site .................................................................................................. 72 
2.  Characteristics of Pharmaceutical Manufacturing Facilities ............................. 75 
3.  Site Survey of the Candidate Site ...................................................................... 80 
4.  Case Study for Design as the Candidate Site .................................................... 82 
5.  Potential Tenants for the Candidate Site ........................................................... 84 
VI. CONCLUSION ....................................................................................................... 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 6 - 
 
TABLES 
Table 1.  Biotechnology Industry Classification in the U.S.    10 
Table 2.  Biotechnology Industry Classification in Korea    11 
Table 3.  Financial Data & Number of Companies of Global Biotechnology Market 18 
Table 4.  Financial Data & Number of Companies by Regions    19 
Table 5.  Scientific Competitiveness: Selected indicators    20 
Table 6.  The Competitiveness Change of Major Biotechnology Business by 2020 27 
Table 7.  Market Size, Manufacturing, &Value Added of Major Biotech Business 27 
Table 8.  SWOT Analysis of Korean BT      29 
Table 9.  Development Phases of Daedeok Techno Valley    38 
Table 10.  The Companies Located in Tuas Biomedical Park    44 
Table 11.  University Park at MIT Project Data         55 
Table 12.  IFEZ Tax Zone Information      66 
Table 13.  IEFZ Public R&D Information      68 
Table 14.  Top Pharmaceutical Companies New Product Pipeline   85 
 
FIGURES 
Figure 1.  Biotechnology Conceptual Flow      12 
Figure 2.  The Drug Development Value Chain     15 
Figure 3.  Approval Cumulative Years      16 
Figure 4.  Expectation of Employment Increase in Biotechnology Industry  21 
Figure 5.  Expansion of Global Operations by Majority Biotech Companies  22 
Figure 6.  Increase in Outsourcing for Contract Sales Force & Contract Manufacturing  22 
Figure 7.  Bio-Vision 2016 Plan       24 
Figure 8.  Bio-Vision 2016 Framework Plans     25 
Figure 9.  Bio-Vision 2016 Second Framework Plan     26 
Figure 10.  Bioindustry Distribution by Industry     32 
Figure 11.  Bioindustry Distribution by Regions in Korea    33 
Figure 12.  Map of South Korea       33 
Figure 13.  The Development of Medical Equipment Industry    36 
Figure 14.  Vision by Years of Wonju Medical Equipment Industry   37 
Figure 15.  Overall Feature of Tuas Biomedical Park     45 
Figure 16.  Cambridge Biotechnology Map      47 
Figure 17.  Biotech Companies’ Segments      48 
Figure 18.  Evolving Number of Firms at Cambridge Cluster    49 
Figure 19.  Specialists Service Providers’ Segments     50 
Figure 20.  University Park at MIT Project Layout     54 
Figure 21.  IFEZ Overview       62 
Figure 22.  Projects in progress on Yeongjong Island     64 
Figure 23.  Market Overview       65 
Figure 24.  Typical Pharmaceutical Manufacturing Facility Cost Profile  76 
Figure 25.  Typical Project Cycle       80 
Figure 26.  Candidate Site Features      81 
Figure 27.  Environment of the Candidate Site     82 
Figure 28.  View of the AstraZeneca Site      83 
Figure 29.  View of the Sky Bridge      83 
 
BIBILIOGRAPHY        88 
 
 - 7 - 
 
I.   INTRODUCTION 
The biotechnology industry has humble roots. Before the founding of Genentech1 31 
years ago, molecular biology was a relatively obscure field, where scientists toiled on 
work that was deemed academically interesting but of little perceived commercial 
application or value.  But, if biotech is an industry of humble beginning, it is also one 
of noble ends, since the technology now has impacts on our daily lives.  A familiar 
example of biotechnology’s benefits is the new generation of home pregnancy tests that 
provide results more quickly and of greater accuracy than previous tests.  In the 
agriculture industry, biotechnology can help improve crop production and meet ever-
increasing demand by increasing yields, decreasing crop inputs such as water and 
fertilizer, and providing pest control methods that are more compatible with the 
environment. 
 
There is no question that biotechnology has an impact on various industries and even 
drives innovation in certain development industries. As a result, almost all countries are 
interested in the technology and have developed a national strategy to improve and 
invest in it.  However, because of high barriers to entry, each country has a different 
position and status.  Some countries, such as the United States start to approach 
profitability while European countries pursue sustained growth, and Asian countries, 
such as Korea enter into emerging solutions.  
 
According to Datamonitor, global biotechnology market value has increased by 13.4%2 
annually since 2002.  Along with the growth of the biotechnology industry all over the 
world, the demand for real estate such as office, laboratory, R&D facilities and 
infrastructure is also increasing.  As a result, real estate for biotech industry becomes 
an important factor for the continued growth and success of individual businesses. Due 
to the nature of the labor and materials involved, biotechnology requires innovative real 
estate designed for maximum efficiency. Selection and integration of the right product 
types in the cluster is also critical for the biotechnology business. Briefly, cluster is 
understood as the geographical concentration of different players such as interconnected 
companies, specialized supplies, service providers, and institutions which compete and 
                                     
 
 
1 Considered founder of biotechnology industry 
2 Biotechnology Industry Organization (BIO), Global Biotechnology 2007 
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cooperate in the same industry. Detail explanation for the cluster will be showed in 
chapter Ⅳ. 
 
In this thesis, the author will define biotechnology by way of an account of how it has 
been conceptualized, and a description of its characteristics. Next, the author will 
outline the market and trends of the global biotechnology field, and then turn to the 
specific case of Korea, assessing, again, the market, trends, demand, and opportunity. 
Finally, the author will analyze a real project, “Yeongjong Project”, sponsored by 
Federal Development LLC for market feasibility and provides a brief proposal for the 
candidate site. 
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II.   WHAT IS BIOTECHNOLOGY 
Because the biotechnology (“BT”) industry is a relatively new one, most real estate 
developers are unfamiliar with biotechnology. In this chapter, the author outlines a 
definition, which varies by countries and institutions and offers a classification template, 
since biotechnology is umbrella term. In addition, risks and characteristics of 
biotechnology are explained. 
 
A.  Definition 
What is biotechnology? 
Using biological processes is hardly a noteworthy event.  Humankind began growing 
crops and raising animals 10,000 years ago to provide a stable supply of food and 
clothing.  We have used the biological processes of microorganisms for 6,000 years to 
make useful food products, such as bread and cheese, and to preserve dairy products.  
Why is biotechnology suddenly receiving so much attention? 
 
During the 1950s and 1970s our understanding of biology reached a point where we 
could begin to use the smallest parts of organisms - their biological molecules - in 
addition to using whole organisms. 
 
A more appropriate definition for the more recent sense of the word would be as follw: 
“New” Biotechnology – the use of cellular and bimolecular 3  processes to solve 
problems or make useful products. 
 
We can get an even better understanding of the term biotechnology by simply changing 
the singular noun to its plural form, biotechnologies.  Biotechnology is a collection of 
technologies that capitalize on the attributes of cells, such as their manufacturing 
capabilities, and put biological molecules, such as DNA and proteins, to work for us.4 
 
According to the Organization for Economic Co-operation and Development (OECD), 
biotechnology is the application of science and technology to living organisms, as well 
                                     
 
 
3 Consisting of or relating to two molecules 
4 Biotechnology Industry Organization (BIO), Guide to Biotechnology 2007 
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as parts, products and models thereof, to alter living or non-living materials for the 
production of knowledge, goods and services.5 
 
What is the biotechnology industry? 
The biotechnology industry is defined as “the high value added industry which 
reprocesses/reproduces the useful product and service for human being from the 
function and information such as inheritance, propagation, growth, self-control, and 
metabolism by taking advantage of biotechnology.” 6   Ultimately, biotechnology 
industry can be summarized in the industry which produces the useful product for 
human being based on biotechnology and creates new products by integrating high 
biotechnology with various types of industrial fields including chemistry, electronics, 
energy, pharmaceutical, environment, agriculture, and food. 
 
B.  A Framework of Biotechnology Industry 
1.  Classification 
Every country has a different definition of biotechnology industry.  It is necessary to 
identify and lay out the range of biotechnology industry before discussing it by 
countries. Ernst & Young, which monitors global biotechnology industry and publishes 
annual reports, classifies the industry into medical diagnosis, genetic/proteinic 
technology, industry bio, new drug discovery technology/service, new drug discovery, 
regeneration medical science, bio agriculture, and others as shown in Table 1.  This 
classification is based on the U.S. market, the world’s largest, and focuses on the 
clinical and health field as it is based on current market size.   
 
Table 1. Biotechnology Industry Classification in the U.S7 
Health and 
Clinical  
Medical Diagnosis, New Drug Discovery Technology/Service, New 
Drug Discovery, Regeneration Medical Science 
Others Genetic/Proteinic Technology, Industry Bio, Bio Agriculture, Others
                                     
 
 
5 OECD, A framework for biotechnology statistics  2005  
6 Biotechnology Industry Organization (BIO), Guide to Biotechnology 2007 
7 Ernst & Young, Global Biotechnology Report 
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Korea Institute for Industrial Economics & Trade (“KIET”) breaks down the 
biotechnology into eight industries as shown in Table 2. Major difference of the U.S 
and Korea classification is that the U.S. market is more sensitive to health and clinical 
whereas Korea is more focused on actual products. 
Table 2. Biotechnology Industry Classification in Korea8 
Classification 
Production Products Biopharmaceutical Industry 
Biochemical Industry 
Biofood Industry 
Bioenvironmental Industry 
Bioelectronics Industry 
Bioprocess and Equipment Industry 
Energy Bioenergy and Bioresource Industry 
Service R&D Bioassay, Bioinformatics and R&D service 
industry 
 
2.  A Conceptual Model Biotechnology Measurement 
Biotechnology encompasses several different research technologies or methods and 
several sectors or fields of application.  As an example of multiple applications, 
recombinant DNA technology can be used to produce large molecule medicines in the 
pharmaceutical sector, create new crop varieties in the agricultural sector, or create 
microorganisms that produce industrial enzymes for the chemical sector.  The variety 
of methods plus the range of applications can lead to large differences in how survey 
respondents might interpret questions on “biotechnology”.  To avoid this problem, 
biotechnology must be carefully defined in order to produce reliable and comparable 
statistics and indicators. 
 
Figure 1 provides a conceptual model for biotechnology framework.  Note that it lies 
within a broader conceptual model covering science and innovation generally.  The 
                                     
 
 
8 KIET (Korea Institute for Industrial Economics & Trade) 
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circle in the top right-hand corner includes the key activities that are the focus of this 
framework: biotechnology R&D and the use of biotechnology techniques to produce 
goods or services.  These activities produce end products (in the dotted hexagon) that 
are outside the current scope of this framework.  End users, either firms or individuals, 
purchase biotechnology products as an input for manufacturing, agriculture or energy 
production.  The central rectangle includes six main biotechnology techniques that are 
the focus of biotechnology R&D or which are used in production.  The left-hand 
rectangle includes the different aspects of biotechnology that the framework is designed 
to measure.  They include biotechnology techniques used in the key biotechnology 
activities. 
 
It is important to note that some firms can be engaged in key biotechnology activities 
and also use biotechnology products.  In such cases, only the firm’s key biotechnology 
activities are covered in this framework.  It is also possible for end users of 
biotechnology products to feed back to key activities, for instance GM9 crops can be 
used as inputs to manufacturing processes based on biotechnology. 
 
Figure 1. Biotechnology Conceptual Flow10 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
 
 
9 Genetically Modified 
10 OECD 
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C.  Risks and Characteristics of Biotechnology 
 
The biotechnology industry is one of the major knowledge-based industries, which 
creates higher value-added business by investing intangible value, and is expected to 
continue to grow steadily in the 21st century.  In addition, because biotechnology is a 
global industry it cannot complete the entire value-chain of the industry within one 
district or country, and absolutely requires the cooperation of multiple districts or 
countries.  A large-scale international cooperation program where scientists and 
research centers are combined organically is on the rise as the field of R&D relevant to 
biotechnology business expands and large-scale investment is required through the Post-
Genome11 era.  The innovative technology development is established for the period 
of Post-Genome era. In addition, the new lines such as Biochip, Nanobiotech, and Bio-
information are created and the development of confusion of IT and BT is accelerated.  
 
1.  Risks and Characteristics 
Ernst & Young summarizes the risks and characteristics of biotechnology as follows:12 
 
Pricing Pressure and Access: The biggest risk facing the biotech industry is the 
prospect of increased price controls and access – a risk that could threaten the survival 
of the industry. The pressure of price controls could hurt commercial incentives and 
lower innovation. In the US in the mid-1990s, when President Bill Clinton’s proposed 
healthcare reforms were under debate, the mere consideration of the possibility of price 
controls led to a significant decrease in the amount of capital made available to fund 
R&D investment, forcing several biotech companies to withdraw planned IPOs.  
 
Raising Capital: Funding has always been a challenge for biotech companies, and many 
companies are now navigating a funding gap as venture capitalists increasingly favor 
investments with more predictable capital needs and exits. 
                                     
 
 
11 The biotechnology company, Celera Genomics announced to solve human genome’s 
map in 2001 since six different research teams including the U.S, the Great Britain got 
together for HGP (Human Genome Project) in 1990. 
12 Ernst & Young, Strategic Business Risk 2008 
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Strategic Alliances: From the earliest days, biotech companies have turned to strategic 
alliances to manage risk, access capital, and increase efficiency.  However, in today’s 
highly competitive deal environment, companies face increasing challenges and new 
risks related to deals. 
 
Demonstrating Value: Biotech companies are facing considerable pressure to 
demonstrate not only efficacy from regulatory requirements but also economic value. 
 
Product Development and Clinical Trials: Clinical trials are increasingly expensive, 
and higher drug development costs put pressure on capital raising and drug pricing. 
 
Regulatory Compliance: Because panelists complain a lack of transparency of 
regulation, the pressures include operating new requirement areas such as post-
marketing monitoring. 
 
Monitoring Drug Safety: A number of recent drug withdrawals from the market after 
approval (e.g., Vioxx and Tysabri) have resulted in significant revenue losses, litigation 
and increased public awareness of drug safety. 
 
Protecting Intellectual Property: Biotech companies face IP (Intellectual Property) 
risks in significant emerging markets. 
 
Accessing Talent: The relatively lower numbers of science graduates, especially in the 
U.S, will result in biotech companies increasingly looking to source talent globally. 
 
Harnessing Emerging Markets: Need to capitalize on the growing importance of 
emerging markets for sales, development and innovation  
 
A single underlying factor is driving several of the biotech risks, and that is the issue of 
ensuring that the industry’s innovation will be funded in the years ahead. It is essential 
that companies are able to price products at levels that provide adequate returns to 
investors so the industry remains innovative and financially healthy. Pricing pressures 
continue to increase in the U.S., and providing access for developing country 
populations will further compound this challenge. Entering emerging market especially 
providing a familiar environment for foreigner should be considered not only for 
potential markets but also for opportunity to expand business globally.  
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2.  Drug Development Value Chain 
 
To better understand biotech’s development process more thoroughly, the author will 
describe the features of its primary exemplar: the drug development value chain. The 
drug-development value chain can be divided into four basic steps: research in which 
promising compounds to treat a particular disease are identified; development where the 
compound is refined and tested in clinical trials in animals and humans; manufacturing, 
where the compound is produced in large quantities; and commercial, including 
activities such as sales and marketing (see Figure 2). 
 
Figure 2. The Drug Development Value Chain13 
 
The FDA requires drugs to undergo three phases of clinical testing on humans. During 
Phase I, a small number of healthy people get moderate doses of the drug in order to test 
the drug’s safety dosing range, and mechanism of action. If this initial test is successful, 
the subjects’ dosage is slowly increased to determine its safety at higher levels.  
During Phase II, a larger group of subjects, who have the disease or condition that the 
drug is intended to threat, is tested in placebo-controlled clinical trials. Phase II 
researchers look for efficacy and continue to study safety and optimal dosing. 
                                     
 
 
13 BIO, Guide to Biotechnology 
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Drugs that pass the first two hurdles then undergo Phase III trials. At this level, the most 
complex and rigorous tests are performed on still larger groups of ill patients to 
ascertain the drug’s safety, effectiveness, and optimum dosage regimens. 
Usually, Phase III procedures employ randomized, double-blind studies with placebo 
control. This means that one group of patients is given the drug while another group 
receives an inert substance. Neither the patients nor their doctors are aware of which 
patients are actually receiving the drug being tested. 
The FDA has estimated that, of 20 drugs entering clinical testing, an average of 13 to 14 
will successfully complete Phase I, of those, about nine will finish Phase II, but only 
one or two are likely to survive the Phase III trials. Even after a drug successfully 
completes Phase III, there is the possibility that FDA will deem the data insufficient for 
approval. Ultimately, only one of the original 20 may be approved for marketing. 
 
With the complex process of development, the drug discovery and development process 
requires a long time horizon (from 10 to 15 years).  During the 1990’s, moreover, 
because of the use of biotechnology, the time to gain the approval for a new drug 
significantly increased.  Figure 3 shows the contribution of each phase to the overall 
completion time. Overall, it takes 14.7 years from target identification to clinical trial.  
 
Figure 3. Approval Cumulative Years14 
 
 
 
                                     
 
 
14 The Boston Consulting Group, 2001 
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The top 10 risks for biotech are concentrated at the sector and operational levels. To 
some extent, this reflects the fact that biotech is truly different from other industries, and 
that the risks it faces reflect its unique challenges and circumstances. Biotech companies 
(and their pharmaceutical counterparts) are some of the most highly regulated 
businesses, and it can consequently take more than 15 years and $1 USD billion to bring 
a product to market. In the U.S. biotech market, there is currently the heavy pressure of 
pricing control, coupled with a high level of strict regulations, making it difficult for 
firms to remain competitive. The author believes it is time for U.S. biotechnology firms 
to set up different strategies for entering emerging markets where there is less pressure 
of pricing control, less regulation, and even high government support. 
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2001 2002 2003 2004 2005 2006
Public Company Data
Revenues 35,985    41,369    46,553    54,613    63,156  73,478    
R&D expense 16,456    22,012    18,636    20,888    20,415  27,782    
Net loss 5,774      12,483    4,548      5,304      4,388    5,446      
Number of employees 191,864  193,753  195,820  183,820  -        190,500  
Number of Companies
Public companies 631         613         611         641         671       710         
Public and private companies 4,267      4,362      4,471      4,416      4,203    4,275      
III.   BIOTECHNOLOGY MARKET OVERVIEW 
 
This chapter will discuss opportunities and how those opportunities are a result of 
global market trends. Furthermore, by introducing the biotechnology vision and plan 
established by the Korean government, the author assesses Korean biotechnology 
markets and trends. At the end, based on research of global and Korea market and trend, 
strengths, weaknesses, opportunities, and threats in the Korea biotech market will be 
analyzed. 
 
A.  Global Biotechnology Market and Trend 
The biotechnology industry, which started with a handful of pioneering companies in 
the 1970s, was initially largely confined to the Boston and San Francisco areas. Since 
then, biotech has grown into a truly global industry, with an established European 
presence and emerging strengths in Asia. 
1.  Growth 
Many research centers forecast that global biotechnology market will continue to grow 
more than 12.6% annually in terms of revenues. Table 3 provides the growth rate of the 
revenues of the global total market, and the number of employees for the period from 
FY2001 to FY2006. In terms of revenues, the growth rate of global biotechnology for 
last six years is steadily high as approximately 12.6%. 
Table 3. Financial Data and Number of Companies of Global Biotechnology 
Market (FY2001-FY2006)15 
(Units: in Millions of USD) 
                                     
 
 
15 Ernst&Young, Global Biotechnology Report, 2003-2007 
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2.  Segmentation of Global Market  
The revenues and the number of employees in FY2006 by U.S., Europe, Canada, and 
Asia are shown in Table 4.  The Asia market constitutes only 4% of total revenue, 
while the share of U.S. market is almost 75%. 
 
Table 4. Financial Data and Number of Companies by Regions16 
(Units: in Millions of USD) 
Global U.S. Europe Canada Asia-Pacific
Public Company Data
Revenues 73,478         55,458         11,489       3,242       3,289         
R&D expense 27,782         22,865         3,631         885          401            
Net loss 5,446           3,466           1,125         524          331            
Number of employees 190,500       130,600       39,740       7,190       12,970       
Number of Companies
Public companies 710              336              156            82            136            
Public and private companies 4,275           1,452           1,621         465          737             
 
The patents environment is a good indicator for predicting whether the biotechnology 
industry is growing or developing since intellectual property such as patents is critical to 
the growth of the biotechnology industry.  In many cases, patents are a startup 
company’s most valuable assets.  As such, patents are essential to securing additional 
capital from investors as these companies and their science grow and develop.  
 
Table 5 is very different when using two other measures – high school science 
proficiency and the growth in biotechnology patent applications. While the first two 
measures (scientific paper citations, share of global biotechnology patents) are 
indicators of an economy’s past and current strengths in science and R&D, the last two 
measures (high school science proficiency, growth in biotechnology) are gauges of 
growth trends and investments in the future. The U.S ranks first using the first two 
measures, but it ranks near the bottom - 20 out of 23 countries – using the last two. 
Conversely, China, India, and Korea rank first, second, and third, respectively, in 
biotechnology patents growth. In other words, as emerging economies like China, India, 
and Korea invest in science education and biotech, it is worth asking where scientific 
                                     
 
 
16 Ernst&Young, Global Biotechnology Report, 2007 
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talent will cluster in the future and where the industry’s growth will occur. 
 
Table 5. Scientific competitiveness: Selected indicators17 
High school
science proficiency
Value Rank Value Rank Rank Value Rank
U.S. 37,822       1 43.3% 1 20 1.5% 20
UK 7,565         2 5.3% 4 -                         2.8% 19
Germany 7,497         3 9.6% 3 14 10.1% 6
Japan 6,298         4 14.1% 2 1 8.2% 9
France 5,172         5 3.6% 5 12 6.3% 14
Canada 4,194         6 2.7% 6 8 5.2% 16
Italy 3,363         7 1.0% 15 22 8.1% 10
Netherlands 2,665         8 1.7% 9 5 5.8% 15
Austaralia 2,273         9 2.1% 7 5 3.9% 17
Switzerland 2,168         10 1.4% 12 10 9.0% 8
Spain 242            11 0.8% 16 22 12.9% 5
Sweden 1,960         12 1.2% 13 13 7.8% 11
China 1,481         13 1.7% 9 -                         49.3% 1
Belgium 1,206         14 1.1% 14 12 6.4% 13
Denmark 1,052         15 1.8% 8 30 7.6% 12
Israel 1,039         16 1.6% 11 -                         10.0% 7
Russia 1,019         17 0.2% 19 20 19.6% 4
Finland 893            18 0.5% 18 1 3.1% 18
Korea 841            19 0.0% -         2 22.4% 3
India 789            below 20 0.8% 16 -                         30.4% 2
Growth in
biotechnology
li i
Scientific paper citations Share of globalbiotechnology patentsCountry
 
3.  Trends 
In late 2006 and early 2007, Ernst & Young surveyed biotechnology company 
executives in the United States, Europe, and Canada, to gather data on their company 
growth plans and global strategy over the next two years.  Responses were received 
from more than 400 companies, representing a mix of early-stage companies and mature 
or newly maturing companies.  
 
The survey reveals an industry with significant growth planned across several fronts. 
Some 94 percent of the respondents said they are “likely or very likely” to increase their 
                                     
 
 
17 Ernst&Young, Global Biotechnology Report, 2007 
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number of employees over the next 24 months. (Figure 4) This result means 
biotechnology market is promising, and most related companies plan to invest their 
businesses for a number of years to come, suggesting that the biotechnology market is 
likely to become even more competitive. 
 
Figure 4. Expectation of Employment Increase in Biotechnology Industry18 
 
 
 
In terms of global strategy, as the industry continues to mature, clinical development 
and contract sales forces companies anticipate significant growth in outsourcing.  As 
shown in Figure 5, the survey reveals that 66% of America’s companies are planning to 
expand global operations and 76% of European companies plan to go out.  In terms of 
outsourcing trend in Figure 6, currently 65% of biotech companies already set up 
contract manufacturing for outsourcing, but they plan to increase that to up 77% from 
65% for the next two years. That means many biotech companies are looking for the site 
to build their manufacturing plants by themselves or for companies who manufacture 
their products globally since 12% difference is significant rate for manufacturing. 
 
 
 
 
 
 
 
                                     
 
 
18 Ernst & Young, Biotech CEO Survey 2007 
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Figure 5. Expansion of Global Operations by Majority Biotech Companies19 
 
 
 
 
Figure 6. Increase in Outsourcing for Contract Sales Force and Contract 
Manufacturing20 
 
 
                                     
 
 
19 Ernst & Young, Biotech CEO Survey 2007 
20 Ernst & Young, Biotech CEO Survey 2007 
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To sum up the global biotechnology market and trends, it is clear that the market size is 
increasing annually and global biotechnology firms plan to invest more. In addition, as 
the top 400 biotech companies have responded to the survey, they determine to use 
more global outsourcing for manufacturing, sales forces, and the like as one way to 
expand their business. 
 
 
B.  Korean Biotechnology Market and Trend 
 
Local biotechnology business in Korea is growing rapidly with the support of the 
government, which began in the early 1980s; however, the industry size is still 
insignificant compared to developed biotechnology countries such as the U.S., Japan, 
and the EU.  Competitiveness in technology is about 60%-70% of the standard of 
developed countries, which is low level except for fermentation technology.  In 
addition, local biotechnology business is only focused on the field of organism process 
and organism medicine; however, technology development in various other fields has 
made progress since the middle of the 1990s. 
 
This section discusses the vision of the Korean biotechnology industry set by the 
government, along with the trends of the industry. 
1.  Bio-Vision 2016 
For a clear understanding of the Korean bio industry, the first and second framework 
plans, as they are referred to by the Korean government, should be explained. Bio-
Vision 2016, Second Framework Plan for Biotechnology Promotion, was established by 
the Korean government to enable Korea to lead the international trends in biotechnology 
in the 21st century. (Figure 7)  As shown in Figure 7, the plan is aimed at strengthening 
the core infrastructure necessary to develop and commercialize world-class original 
technologies during 1990s. It is founded on the research basis established in the First 
Frame Plan for Biotechnology Promotion.  
 
As a result the First Framework Plan for Biotechnology Promotion, Korean 
biotechnology began to produce its own creative achievements rather than merely 
modifying the results obtained by other countries: this in turn led to other industrial and 
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economic achievements. According to Bio-Vision 2016, by 2001 Korea biotechnology 
competitiveness achieved, by 2016 based on foundation of previous stage, Korea  
Biotechnology market occupancy ranks top 7th. 
 
 
Figure 7. Bio-Vision 2016 Plan 
 
 
Based on the establishment of a solid research foundation during the first framework 
plan, the Korean government has implemented the Second Framework Plan for 
Biotechnology Promotion to secure original technology and upgrade the infrastructure 
for industrialization.  Figure 8 explains the difference between the First Framework 
Plan and the Second Framework Plan. Whereas the first framework plan aimed to 
establish a research foundation of biotechnology with government, institutional support, 
the second framework plan focuses on industrialization of the field. 
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Figure 8. Bio-Vision 2016 Framework Plans 
 
 
According to the Bio-Vision 2016 in Figure 9, the vision of Korea bio industry is to 
create a life-oriented society and bio-economy within 10 years. Bio-Vision 2016 is 
aimed at achieving the seventh place global ranking for Korea in terms of biotechnology. 
Bio-Vision 2016 has also set the following targets for thesis, patents, human resources, 
and markets.  First, the plan targets the seventh place by 2016 (from 13th in 2005).  
Second, as for patents, the plan targets the seventh place by 2017 (from 14th in 2005).  
Third, as regards to the number of holders of master degrees and doctorates, the plan is 
to employ 17,300 engineers in 2016 (up from the 9600 in 2005).  Lastly, with regard to 
the market, the plan aims to increase market size to $65 billion USD by 2016 (from $2.9 
billion USD in 2005).   
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Figure 9. Bio-Vision 2016 Second Framework Plan 
  
 
 
 
 
 
 
 
 
 
 
 
2.  Trends 
 
Korea Institute for Industrial Economics & Trade (KIET) announced that three major 
industries - advanced biomedicine, bioorgan, and biochip would be promoted 
intensively in Korea sine those industries is relatively well established and has founded 
good infrastructure.  According to KIET, local biomedicine, bioorgan, and biochip 
businesses are expected to grow an average of 19% annually based on manufacturing 
standards until 2020, which well exceeds global market growth, 14.1%. 
 
The competitiveness of local infrastructure, resource (basic research), product 
technology, and marketing was estimated at 55-75 compared to the U.S., which 
represents the standard at 100. This means that within the developed market, the U.S. 
reached 100 in terms of its competiveness, as compared to the degree of Korea’s 
biotechnology development (Table 6). It is projected that local competitiveness will 
increase by 80-95 degree in 2020. For example, infrastructure and product technology is 
95, which is almost equal to the degree of development by the U.S.; resource (basic 
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research) is expected to reach 80. 
 
Table 6. The Competitiveness Change of Major Biotechnology Business by 202021 
2005 2010 2015 2020
Infrastructure 75 80 90 95
Resource (Basic research) 60 65 70 80
Product Technology 75 80 90 95
Marketing 55 65 80 85  
(U.S. market assumes 100 compared to Korea market) 
 
According to KIET, the global market share of local biomedicine, bioorgan, and biochip, 
which are major biotechnology businesses, will increase from 1.4% in 2005 to 2.7% in 
2020.  Also the value-added amount in 2005 is estimated at USD 0.7 billion and this 
may increase by USD 1.8 billion in 2010 and USD 2.8 billion in 2020, which means 
that the value-added volume compared to the global market will be increasing from 
1.9% in 2005 to 3.8% in 2020. 
 
Table 7 shows projections for market size, manufacturing, and value added of major 
biotechnology business. Market share of manufacturing business in Korea starts from 
1.5% in 2005 to 2.7% by 2020. 
 
Table 7. The Market Size, Manufacturing, and Value Added 
of Major Biotechnology Business by 202022 
(Units: in Millions of USD, %) 
2005 2010 2015 2020
Global 72,060.4  164,214.2  371,438.3  517,946.1  
Korea 1,224.0    3,137.6      7,463.0      11,594.5    
% 1.7 1.9 2 2.2
Global 72,060.4  164,214.2  371,438.3  517,946.1  
Korea 1,040.0    2,964.5      7,816.4      13,967.9    
% 1.4 1.8 2.1 2.7
Global 33,060.7  74,433.2    166,767.4  230,468.3  
Korea 628.9       1,825.4      4,885.3      8,792.7      
% 1.9 2.5 2.9 3.8
Market Size
Manufacturing
Value-added
 
                                     
 
 
21 Korea Institute for Industrial Economics & Trade, 2006 
22 Korea Institute for Industrial Economics & Trade, 2006 
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C.  Strength, Weakness, Opportunity, and Threat of Korea BT Market 
 
The following SWOT analysis Table 8 presents the Strength, Weakness, Opportunity, 
and Threat within Korea’s biotechnology business. To sum up, Korean biotechnology 
has achieved significant new drug development, and there are many R&D centers and 
institutions to support research and development. In addition, advanced R&D and 
environment more familiar to foreigners exist. On the other hand, lack of experience 
entering the global market and lack of infrastructure constitutes clear weaknesses. 
Furthermore, strong competition with China and India expected, and while short-term 
investment vehicles are common in Korea industry, biotechnology industry requires 
long-term investment.  
 
Throughout this chapter, the author has demonstrated that the worldwide biotechnology 
market is growing substantially, and most global firms seek strategic locations for 
outsourcing of manufacturing, sales forces, etc. Korea’s BT has just constructed basic 
infrastructure for biotechnology development, but at the same time it does have highly-
skilled manpower in a number of R&D centers and institutions. In addition, the Korean 
government has established plans to develop biotechnology nationally, with levels of 
supporting administration and finance. Under the circumstances, Korean BT market 
might be the opportunity for global BT firms in terms of saving operating costs and 
entering new market. 
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Table 8. SWOT Analysis of Korean BT 
Strength Weakness 
- Korea has experienced to develop 
generic medicine, improved medicines 
based on the compounding technology 
of organic chemistry, and exported the 
products.  
- The R&D regarding the up-to-date bio 
products such as cell therapy products 
and gene therapy products is 
progressing and the products in clinic 
stage are increasing in domestic and 
foreign. 
- The performance of high-tech study is 
increasing by public organizations such 
as colleges and R&D centers, based on 
R&D investment with government 
support. 
- Korea biotechnology business is still at 
the first stage quantitatively and 
qualitatively. 
- Many biotech firms are small 
businesses and most products are low 
value added or in R&D stage. 
- Manufacturing infrastructure and 
technology for industrialization are 
weak. 
- Few local firms have experienced 
overseas expansion, while global 
expansion is essential for biotech 
industry. 
Opportunity Threat 
- Biotechnology market is expanding 
due to the environmental change such 
as aging and environmental pollution. 
- Developed technology development 
environment and technology 
comparing to competing countries, 
India and China. 
- Biotech business needs high cost and 
long term R&D period, while local 
finance environment generally allows 
short term investment. 
- The separation between reality and 
expectation from rash 
commercialization and excessive 
advertising brought social 
disappointment. 
- The competition of key technology 
development among developed 
countries becomes intense more and 
more and price competitive is low 
comparing to competing countries, 
India and China. 
- Networking such as strategic 
cooperation and M&A is week. 
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IV.   BIOCLUSTER CASES 
 
This chapter discusses five biocluster cases: two cases for Korea, one each for 
Singapore, the United Kingdom, and the United States. By describing the approach of 
different regional and marketing locations, the author defines biocluster and the 
characteristics of the clusters.  
 
Each cluster case is analyzed with different approaches in order to better understand 
success factors and considerations of the development. For example, some cases tell 
how to integrate the components of the cluster such as government, educational 
institutions, or industry, while others explain how the processes occur when developing, 
and the trend of the cluster historically to outlook next trend.  
 
First of all, as most real estate developers are unfamiliar with biocluster, a definition of 
biocluster, and advantages and disadvantages of it will be explained. 
 
A.  Understanding Biocluster 
Biocluster is a cluster focusing on the biotechnology sector, where cluster is understood 
as the geographical concentration of different players such as interconnected companies, 
specialized suppliers, service providers, and institutions, which compete and cooperate 
in the same industry. Cluster development is a complex process and usually involves a 
number of players that include governmental departments, economic development 
agencies, public administrations, universities and research centers, companies of 
different types, and financial institutions.  
1.  Advantage and Disadvantages 
The definition of cluster itself suggests that clustering may lead to significant 
advantages for firms. They may take advantage of the strong demand in the location, the 
large supply of manpower (even highly qualified and specialized), and the network of 
complementary strengths in neighboring firms. Particularly in high technology 
industries, geographical proximity plays a pivotal role in the early stages of the life 
cycle of a product or technology, facilitating the use and transfer of tacit knowledge that 
is a key to successful development.  
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Porter in his Adam Smith Address (1998) identifies three kinds of advantages in 
clustering: 
Productivity advantages: These advantages derive from the use of better and cheaper 
specialized inputs (components or services), which themselves come from minimal 
inventory requirements and lower transaction costs resulting from geographic proximity 
and the establishment of high trust relations among companies within a cluster. 
Moreover, joint purchasing services or shared infrastructures (particularly high-tech 
facilities) may reduce fixed costs for existing companies and initial investments for new 
ventures; 
Innovation advantages: Proximity between customers and suppliers facilitates the 
transfer of tacit knowledge. Moreover, the proximity to a knowledge center offers a 
strong potential for innovation and, allowing critical mass to be gained, particularly for 
pre-competitive activities such as basic research. Finally, localized benchmarking 
among players in the cluster and the great availability of a qualified labor market can 
strongly improve the capacity to innovate. 
New business advantages: Due to better circulation of information about market 
opportunities and potential, barriers and risks for new firms can be lower for the clear 
perception of unfilled needs. 
Whereas major disadvantages concern is congestion and competition in output and input 
market according to Swann, Prevezer, and Stout (1998) in their book The Dynamics of 
Industrial Clustering. 
Congestion and competition in output markets: According to microeconomic theories, 
a increased number of competitors in the same geographic area may reduce per-firm 
sales, prices, profits and growth. These effects, however, actually start to dominate 
demand side advantages when congestion becomes heavy, suggesting that there may be 
diminishing (and eventually negative) returns to locating in a cluster as it reaches its 
maturity. 
Congesting and competition in input market: It is expected that effects of the cost of 
real estate or the cost of labor. It is expected that these effects come to dominate for new 
firms when the cluster reaches its maturity. 
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B.  Korean Biocluster Cases 
1.  Statistics 
a. Bioindustry distribution 
Korea Institute for Industrial Economics & Trade (KIET) provided the information on 
bioindustry distribution is as shown in Figure 10.  Biomedical industry takes the 
biggest share of this distribution and actual operating firms are 29% of the total. This 
means biomedical is dominant within the biotechnology industry in Korea.   
Figure 10. Bioindustry Distribution by Industry23 
 
b. Regional distribution 
Most local bioindustry firms are centralized in metropolitan areas which include 
Kyunggi (32.9%), Seoul (21.5%), and Daejeon (8.9%). In case of Incheon, it has low 
portion around 3% but it also has strategic advantage since it is located adjacent to 
                                     
 
 
23 KIET, Bioindustry Statistics (2006) 
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Seoul 
Wonju 
Daejeon 
Incheon
Kyunggi, largest region, and Seoul. 
Figure 11. Bioindustry Distribution by Regions in Korea24 
 
Figure 12. Map of South Korea 
 
Left illustration, Figure 12 shows map of South 
Korea. Following Korea two cases are located 
at Wonju for Medical Techno Valley and 
Daejeon for Daedeok Techno Valley. Incheon 
for Yeongjong Project is located at the west 
coast of Korea. 
 
 
 
 
 
                                     
 
 
24 KIET, Bioindustry statistics (2006) 
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2.  Case 1, Wonju Medical Techno Valley 
 
Wonju Medical Techno Valley is the largest medical equipment manufacturing cluster in 
Korea. Here the author gives a story of the birth, history, conditions surrounding the 
area, product types of the cluster, and how components such as government, industry, 
and schools have been integrated. 
 
 
a. History and Overview 
Wonju Medical Industry Techno Valley (“Techno Valley”) benchmarked Tuttlingen, a 
medical equipment specialized city in Germany.  Techno Valley selected the 
specialized industries focusing on electric medical equipment and remedial medical 
equipment and targets an independent industrial complex with its nourishing autogenous 
firms and its support and cooperation from those companies. 
 
In addition, the Techno Valley helped the medical industry stabilize and build a network 
in the cluster by supporting R&D, marketing and management, funding, training and 
education, information, business incubation, and the like.  
 
The city of Wonju and Yonsei University established Techno Valley at Wonju which is a 
mostly barren city with some medical equipment business.  The city of Wonju needed 
new innovative strategies to survive and Yonsei University needed a solution to prevent 
a decrease in the student population and revitalize R&D.  Multiple projects have been 
developed since the Techno Park R&D Center Development, which was promoted by 
the Ministry of Commerce, Industry and Energy.  In 1999, the Wonju campus of 
Yonsei University received permission from RRC businesses to conduct studies of core 
technologies for nine years in addition to the central government and it was nominated 
officially as Business Incubator (“BI”) by the Small and Medium Business 
Administration that same year.  In addition, the 10,000㎡ (2.47 acres) Techno Park for 
post-BI was established within the Taejang Industrial Complex of rural areas and about 
20 firms incubated there by the time BI moved in. 
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b. Conditions surrounding the area 
There are five universities that supply high-quality researchers and technicians and, 
three general hospitals support clinical researches around the area. The cluster is 
designated a venture promotion district by the Small and Medium Business 
administration and as an innovation cluster model complex.  
 
To assist international firms in getting established in the cluster and to assist local firms 
to better communicate with international firms, Yonsei University provides language 
courses by each native speaker and campus facility. 
For transportation, the cluster is at a strategic center of logistics and transportation with 
gjong and Jungang Expressways and there is a daily flight between Wonju and Jeju 
Island. 
 
c. Basic concepts for the development of medical equipment industry 
Figure 13 shows how the cluster develops as a medical equipment industry. The core 
business of the cluster is the Techno Valley that controls each component. Schools 
provide human resources, and play a role in constructing infrastructure and supporting 
R&D. Local government helps establish the infrastructure to make the area a friendly 
environment with a medical equipment cluster and taxes benefits. Companies promote 
the medical equipment industry and start businesses by taking advantage of the schools’ 
resources and government support. 
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Figure 13. The Development of Wonju Medical Equipment Industry 
 
 
d. Product type 
Wonju Medical Clusters consists of the following three complexes: 
 
 Medical Industry Techno Tower – AHSOL, AIRMED et al: total 12 tenants 
 Wonju Medical Technology Techno-park – BeEAUTO, ELBIO et al: total 26 
tenants 
 Donghwa Medical Instrument Complex – AILAB, BIOPROTECH, etc total 16 
tenants 
 Medical Venture Industry 
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e. Vision of the cluster 
The cluster started in 1998 with no infrastructure and business but now in 2008 employs 
1,500 and produces medical equipment valued at $250 million (USD). By 2016, the 
cluster plans to become the world’s fifth leading producer of medical equipment 
manufacturing and produce $1.2 billion USD. Figure 14 illustrates details this vision 
step by step. 
 
Figure 14. Vision by years of Wonju Medical Equipment Industry 
 
The characteristics of Wonju Meical Cluster are initiated by the government and 
educational institution. Because Yeonsei Uni has strong research of medical industry, 
the government could easily coorperate with the university to support to establish 
infrastructure of medical equipment. Moreover, the cluster that has similar medical 
equipment concept didn’t exist any location in Korea other than Wonju. These 
characteriscs could lead the cluster be a leading medical equipment cluster in Korea. 
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3.  Case 2, Daedeok Techno Valley  
 
This case study explains more about the development process of a large scale cluster in 
Korea from a real estate developer’s 
point of view. 
 
Daedeok Techno Valley (“DTV”) is 
established by special corporations 
that consist of private company 
(Hanwha), national bank (Korea 
Developmen Bank), and local 
government (Daejeon city). The 
Hanwha is responsible for the DTV development project and management, KDB (Korea 
Development Bank) administers the development fund loan, and Daejoen Metropolitan 
City is interested in bio and high-tech venture companies. 
 
a. Development Phases 
Daedeok Techno Valley is constructed on a 4,257,000 m2 (1,051 acres) site near 
Gwanpyeong-dong, Yeseong-gu, Daejeon Metropolitan City, Korea. It is a three-phase 
project, which began in 2001 and was scheduled for completion in 2007 as shown Table 
9. 
 
Table 9. Development Phases of Daedeok Techno Valley 
Classification Area Period 
1st Phase 924,000 m2 228 acres Nov 2001 ~ Jul 2004 
2nd Phase 1,584,000 m2 391 acres Jun 2003 ~ Jun 2006 
3rd Phase 1,749,000 m2 432 acres Apr 2005 ~ Dec 2007 
Total 4,257,000 m2 1,051 acres   
 
b. Development Layout 
The project includes industrial, residential, commercial, leisure and public sites. 
 
 - 39 - 
 
 Industrial 
The industrial site (red area) is in the Gapcheon 
area of the north complex and is composed of 
general industrial and semi-industrial 
complexes, which includes factories and offices. 
Research institutes of venture companies 
equipped with cutting-edge technologies 
including IT, BT, NT, and RT, are moving there. 
Daedeok Techno Valley (DTV), which is at the 
center of Daedeok R&D special district and 
forms a dynamic high-tech industrial cluster 
with 1,000 venture companies and 200 research institutes in the Daedeok research 
complex. It attracts the top-level graduates from KAIST, ICU, etc. and creates an 
infinite synergy based on industry-university-research cooperation. This makes DTV 
the best productive domestic high-tech venture industrial complex equipped with a first-
rate industrial base. 
 
 
 Residential 
The DTV residence complex (red area) is a 
combination of high-rise apartment buildings, 
townhouses, and detached houses. It offers 
superior residential conditions including 10 
new elementary, middle and high schools 
equipped with state-of-the-art facilities, as 
well as the Gwanpyeong River Ecological 
Part and a waterside park. The residents in the 
hi-tech apartments and suburban-style houses 
will enjoy the pleasures of nature and the 
convenience of the city. The project brings new value and satisfaction to their quality of 
life. 
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 Commercial, Leisure and Public 
The various commercial facilities (red area) 
are strategically located in the complex to 
facilitate self-sufficiency, efficiency and 
balance among the multiple functions of this 
well-planned urban development. 
In addition, tourism and on-site recreational 
facilities will develop into a place for leisure 
activities within the complex. It will also 
include a cluster of landmark facilities such 
as hotels for foreign buyers visiting the 
enterprises housed in the complex and domestic business tourists, using the water park 
and theme parks.  
A high level of education is demanded in the residential complex. Therefore, five 
elementary schools, three middle schools, and three high schools are planned. The 
schools are expected to exceed OECD standards in terms of the number of students in a 
class. A foreigner’s school will be built for foreigner laborers as well. 
 
Finally in Daedeok Techno Valley, 10 neighborhood parks and children parks will be 
constructed on a site 24,000 m2. The neighborhood park at the center of the complex 
will be a venue for outdoor cultural activities including festivals and events. It will be 
accessed and used by various classes of residents and utilized as a place for X-games 
and ecological learning. 
 
c. Characteristics 
Its absorption is currently more than 95% in most phases. What characteristics and 
factors lead to such successful results will be explained. 
 Distinct project initiators 
The synergy effects are maximized thanks to the complementary nature offered by the 
respective expertise of each of the stakeholders, including Hanwha Group's business-
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acumen and management know-how, Daejeon City's administrative services 
contribution, and Korea Development Bank's capital strength 
 
 Carefully phased development approach 
A three phase development approach was adopted, taking into consideration initial 
investment risks and the macro economy. In addition, the phased promotion of the 
project helps reduce investment risks, minimize unsold land, and prevent long-term 
negative ripple effects 
 
 Providing a new model for an industrial complex 
This type of complex environment reminds people more of a research complex rather 
than a typical industrial complex. In addition, a new concept is introduced into this 
complex, which harmoniously combines the elements of an industrial complex 
(production) and a residential/commercial complex (consumption) in a synergistic entity. 
A pleasant environment and culture-friendly city is designed, taking into consideration 
the quality of life of its constituents by following: 
 
1. The introduction of varied skylines in the residential complex; 
2. The presence of Gwanpyeong River ecological park and waterside central park; 
3. The added beauty of splendid lighting of bridges and overpasses; 
4. The preservation of a mountain-type neighborhood park; 
5. The installation of underground power lines, and 
6. The planned construction of leisure and multi-function sports facilities. 
 
 Unique marketing strategies 
First, pre-marketing activities shall be conducted after thorough investigation of demand 
and of comparable prices. Secondly, a drop in real estate demand and local limitation 
shall be overcome through encouraging potential demand. In other words, their target 
market is not only local but also national through aggressive market.  
This mega development represents the different market strategy. Previously, the target 
market was limited to local but now their target tenants are not only local but also 
national even global. For another characteristic of the development, in order to meet 
national and global standard, the development also provides high quality residential, 
office and entertainment complex. The development now focuses on more amenities for 
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resident and employees. The trend tells the development should consider not only 
property itself but also people who use the properties to be successful. 
 
C.  International Biocluster Cases 
1.  Case 3, Tuas Biomedical Park in Singapore 
a. Overview of Tuas Biomedical Park 
 
Singapore’s government has developed biomedical industry seriously upon the slogan 
of “The Biopolis of Asia” to create new R&D, business opportunity, and employment 
since 1990s.  In 2000, the Singapore government announced the BMS Initiative25 and 
makes every effort to attract foreign investment and overseas labor. This is done by 
publicizing the advantage of geopolitical characteristics, located in the center of 
ASEAN26, the protection system of intellectual property rights, the global standard 
educational system, and cultural facilities. 
 
                                     
 
 
25 Economic Development Board (EDB)’s BMS group and Bio-One Capital, as well as 
A-STAR’s BMRC (Bio Medical Research Council) work in close partnership. The goal 
is to develop the BMS cluster – comprising pharmaceuticals, medical technology, and 
biotechnology and healthcare services – into a key pillar of the Singapore economy.  
The three groups adopt an integrated approach to develop Singapore’s industrial, 
intellectual and human capital to support the BMS initiative. 
26 Association of  Southeast Asian Nations 
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The biomedical sciences industry is a one of 
the Singapore’s missions and a key growth 
engine for Singapore’s economy. 
Manufacturing capacity has been expanding 
along with the rapid development of R&D 
expertise and capabilities. By locating their 
business operations in Singapore, companies 
are able to leverage Singapore’s strong intellectual property (IP) protection; strong 
government support and thriving biomedical sciences community. 
JTC27 has developed a wide spectrum of industrial facilities in Singapore catering to 
the specific needs of biomedical manufacturing activities. The 183 hectare Tuas 
Biomedical Park 1 (TBP 1) and the 188 hectare Tuas Biomedical Park 2(TBP2) are 
dedicated to manufacturing-related activities for pharmaceuticals, biopharmaceuticals, 
biologics, vaccine, medical devices and nutritionals related companies. Biopolis at One-
North28 is a research and meeting point for talent in the biomedical sciences. Scientists 
and researchers work together in vibrant R&D environment to spur new discoveries and 
advances in the biomedical sciences. 
Tuas Biomedical Park is designed for bulk active pharmaceutical and biopharmaceutical 
manufacturers. Key infrastructural provisions of power, water, telecommunication, gas 
and sewer requirements are available in the park. In addition to hard infrastructure, JTC 
has invested approximately $6 million in landscaping to create a conducive and 
inspiring environment for the knowledge based cluster in the park. As part of the 
                                     
 
 
27 JTC Corporation (“JTC”) is established as the affiliated organization of Ministry of 
Trade and Industry on June 1968 and takes charge of planning, development, and 
management of business infrastructure and business parks.  JTC developed 38 
industrial complex (approximately 7,000 company residents), 2 business parks, 3 
semiconductor complexes, 1 biomedical park, and chemistry complex of Jurong Island.  
In 2000, JTC is chosen as the Master Developer of One-North project.  JTC, an 
affiliated organization of government manages the price of industry sites to make 
companies competitive by connecting with the market price.  Providing the innovative 
business environment which integrates ‘work, residence, culture, and education’ in one 
community is JTC’s goal from now on. 
28 One-North project is a long term project (183-hec) that provides a biomedical, IT, 
knowledge-based cluster supported by the Singapore government. 
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landscape enhancement project, a landmark sculpture now stands at the park’s entrance 
to mark the gateway into Asia’s premier Biomedical Park. 
 
b. Information on Companies in Tuas Biomedical Park 
 
The biggest tenant of the park is Merck Sharp who entered in 1998 and then Abbott 
who recently joined in the park. Along with the development of Tuas 2 Park, the science 
park has become more famous and attractive to global pharmaceutical firms. 
Table 10. The Companies located in Tuas Biomedical Park 
Bio Pharmaceutical Companies Land Allocated (ha) acres Year of Entry 
Merck Sharp & Dohme  
(Singapore) Ltd 19.4 48 1998 
Wyeth Nutritionals  
(Singapore) Pte Ltd 8.6 21 1999 
Pfizer Asia Pacific Pte Ltd 9 22 2000 
CIBA Vision Asian Manufacturing 
and Logistics Pte Ltd 5 12 2003 
Novartis Singapore Pharmaceutical 
Manufacturing Pte Ltd 8 20 2004 
GlaxoSmithKline Biologicals  
(Singapore) Pte Ltd 8.8 22 2005 
Lonza Biologics  
(Singapore) Pte Ltd 4.2 10 2006 
Abbott Manufacturing  
Singapore Pte Ltd 16 40 2006 
Lonza Biologics Tuas Pte Ltd 4.2 10 2007 
Genentech Singapore Pte Ltd 8.2 20 2007 
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Figure 15. Overall Feature of Tuas Biomedical Park 
 
 
Figure 15 shows the location of Tuas Park 1 (TBP), and Tuas Park 2 (TBP2) including 
tenant lists of the site. 
 
Overall, Singapore is efficiently connected among government ministry, private and 
public R&D, institutions, and universities. In addition the culture is willing to freely 
adapt new technology and research either from domestic or international sources. 
Regarding finance, the government supports the cluster under public-private partnership 
since the government recognizes that initial investment to develop biotechnology 
requires large amounts of capital. They also do not hesitate recruiting professionals from 
other countries if they think the professionals are qualified. These are the reasons the 
cluster is renowned internationally. 
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2.  Case 4, Cambridge Cluster in United Kingdom 
a. Overview of the Cluster of Cambridge 
The industrial biotechnology cluster within Cambridge emerged in the early 1980s in a 
high-tech environment created by existing electronics and computing industries. Initial 
companies were founded within the Cambridge Science Park (owned by Trinity College 
and the University of Cambridge), which itself was built to attract computing companies. 
A national strategy paper was published in the mid 1970s by the British government 
with the intention of making universities more proactive in industry, and this resulted in 
the creation of initial science park buildings by Trinity College. There were no 
buildings specifically for biotechnology companies and college did not build with the 
college acting as landlord only. Now, the Park is dominated by biotech companies and 
viewed primarily as a biotech location. The availability of scientific premises was 
supported by a change in attitude from some major investors within the Cambridge area. 
Barclays Bank, one of the largest banks in Britain started investing in more high-tech 
industry and venture capitalists followed suit. The number of biotech companies grew 
steadily until the mid 1990s, when a global explosion of investment in high-tech 
industries accelerated company creation at a sustained rate. 
Figure 1629 illustrates of the location and geographic information of the cluster. The 
cluster consists of 16 science parks including laboratory and R&D facilities and two 
large educational institutions 
  
                                     
 
 
29 . The illustration’s complexity makes it hard to read, so the following link provides a 
PDF version of the map. http://www.cambridgenetwork.co.uk/docs/Biotech_Map.pdf   
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Figure 16. Cambridge Biotechnology Map 
 
b. Major actors in the cluster 
This analysis takes into account three players; the biotech firms (BFs), the industrial and 
research environment and the financial environment. 
 
 Biotech Firms (BFs) 
Cambridge currently has over 215 biotech companies, over 350 specialist service 
providers with biotech expertise, over 30 research institutes and universities, over 20 
multi-nationals in pharmaceuticals, agriculture and food, and four leading hospitals 
involved in research and working with biotech.  
 
They have built a strong cluster profile as a center for early stage companies with high 
growth rate and innovative technologies. There are also large biotech companies 
scattered throughout the region. Traditionally, large companies such as Celltech and 
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Cambridge Antibody Technology have been classified as large companies based on a 
total number of employees exceeding 250. These companies have a very different 
profile from pharmaceutical companies, operating on biotechnology models rather than 
the classical pharma structure. For example, Cambridge Antibody Technology has no 
large-scale manufacturing and its first product for registration is being handled through 
a partner. 
 
Figure 17 depicts the biotech companies’ segments in the cluster. The largest sector is 
pharmaceutical products and services around 55%.  
 
Figure 17. Biotech Companies’ Segments30 
 
Figure 18 illustrates the speed at which the Cambridge cluster developed. As indicated 
by the number of pre-1984 companies, clusters originated were in the early ‘80s. Each 
column indicates an increasing number of firms each year. However, the most rapid 
period of growth is 1995-1999. The growth is a result of two main factors; first, 
                                     
 
 
30 ERBI (Europe’s leading regional biotechnology industry group) 
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commercial awareness of biotechnology boomed during this period and it suddenly 
became feasible to start a biotech company either from academic start-ups or big 
pharma origins; and secondly, a rapidly growing global economy fuelling large venture 
capitalist investment in a broad range of companies.  
Overall number of development of the area is now decreasing since 1999 because most 
biotech firms strategically have been seeking location having lower costs and less 
regulation. 
Figure 18. Increasing number of firms at Cambridge Cluster31 
 
 Industrial and Research Environment 
 
Besides a strong industrial base, the research environment in the area of Cambridge 
represents a key driver for the development of the cluster itself. The Cambridge cluster 
is synonymous with the University of Cambridge and is closely linked with the 
biotechnology cluster. It could not be described as having been instrumental in the 
formation of the cluster from a commercial angle; the University has been slow to 
realize the commercial potential of its research and only now do we see startup 
                                     
 
 
31 ERBI  
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companies in significant numbers from the university. Trinity College, within the 
University has the strongest commercial links with the biotechnology cluster as it 
developed and owns the Cambridge Science Park. 
 
 Financial Environment 
 
With few exceptions, startup money is provided by national and international venture 
capital. Business Angels are beginning to take an interest in biotechnology funding, 
particularly with the opening of Library House (a facility designed to act as a focal point 
for investors) but their contribution is still low compare to venture capital. Commercial 
banks play little or no role in staring up biotechnology companies because of their high-
risk nature and this shows no sign of altering. Finally, public funding is not available in 
Cambridge and this represents quite an exception in the European biotech clusters. The 
British Government does not invest in UK biotechnology firms. Small-scale research 
programs are available but these are for individual research projects and are relatively 
low cost programs. 
 
Figure 19 indicates the nonfinancial environment of the Cambridge cluster. Technical 
services account for 40%, and financial services around 9%. It reasons that other service 
providers, besides the financial sector are very important factors to the success of the 
cluster. 
Figure 19. Specialists Service Providers’ Segments 
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c. Driving forces and the key factors of the cluster 
Availability of seed and venture capital: Despite the lack of effective public funding 
programmes in the area, there was a great number of venture capitalists (both local or 
international, with businesses in the area) investing in biotech, along with business 
angels and other small investors focused on the seed stage financing. 
Presence of mechanisms to attract key scientific people: This contributes in creating 
a leading-edge scientific base. The University of Cambridge strongly invested in the 
specialization of its biotech-based departments, reaching the excellence in different 
scientific and technological fields. 
Environment of entrepreneurial culture among scientists: Even if, as noted, the 
direct creation of spin-offs from the University of Cambridge came later, since from the 
beginning the commercial “taste” of its researchers led to the birth of many independent 
start-ups, which exploited the results of earlier successful researches. 
Networking culture: Networking culture is the establishment of close relationships 
within universities and research centers and between the research centers and existing 
companies in the geographical area of the cluster. 
International promotion of the cluster: This is achieved through a centralized strategy 
that includes the creation of “cluster representatives”. This strategy helps to attract new 
sites form external companies, offering them a clear motivation to move to the cluster of 
Cambridge. 
 
3.  Case 5, University Park at MIT in the United States 
 
The United States is the largest biotechnology market in the world. It accounts for more 
than 75%32 in terms of revenues, which means the U.S market is one of the important 
cases and should be considered a market for Korea to enter.  
The 27-acre University Park at the Massachusetts Institute of Technology (MIT) is the 
place where the author resides. The author believes it is well designed and eco-friendly, 
                                     
 
 
32 Table 4 
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since residents including the author do not readily recognize that laboratory and R&D 
facilities are located adjacent to the living area. This cases study examines the process 
and phases of development of the cluster and what are the factors should be considered 
when developing biocluster.  
 
a. Overview of University Park at MIT 
University Park at MIT is a mixed-use urban campus that features offices, R&D 
focusing on biotechnology, and residential, hotel, and retail structures. Adjacent to the 
campus of the Massachusetts Institute of Technology, the development was initiated by 
MIT and undertaken through a joint venture with Forest City Enterprises. 
Conceived as a technology-oriented business park providing state-of –the-art, high tech, 
flexible, first-class facilities in a thriving campus environment, University Park has 
evolved into one of the premier centers for biotech and biomedical research in 
Cambridge. When fully developed in 2005, University Park will comprise 213,755 m2 
(2.3 million square feet), including more than 148,700 m2 of office and research space, 
a 210 room hotel and executive conference center, 100,000 m2 of retail space and 9,300 
m2 restaurants, 460 rental housing units, three structured parking facilities for 2,800 
cars, and 1.6 hectares of parkland. 
 
b. Marketing for Biotech firms 
Forest City’s strategy for University Park—with its proximity to MIT and Harvard—
was to develop buildings flexible enough to address the evolving needs of high-tech 
companies, while responding to fundamental shifts in the high-tech industry over time. 
The first buildings targeted high-tech industries such as defense, computer, and software 
firms. In the late 1980s, however, just as these first buildings were completed, demand 
from these previously hot sectors in Cambridge slowed and a new technology-based 
industry—biotechnology—was emerging from university research laboratories. Startup 
biotech companies may require as long as a decade to achieve significant revenues, let 
alone a profit, so many developers and lenders were not inclined to risk their capital to 
build facilities for the fledgling biotech industry. Forest City, however, while 
recognizing the inherent risk, also understood this opportunity to serve an emerging 
market niche during a time when other sectors of the economy were in decline. 
The flexibility built into the structures at University Park—generous floor-to-ceiling 
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heights, large ventilation shafts, and greater-than-average power capacity—was 
originally geared toward high-tech users but also met the functional needs of the 
growing biotech sector. In addition, biotech research facilities have significant HVAC, 
plumbing, and electrical distribution requirements, driving the cost of improvements to 
a level three to four times that of traditional office space. Working creatively with 
lenders, Forest City identified ways of financing tenant improvement allowances of $75 
to $90 per square foot, achieving commensurately higher rental rates in return. 
Experience has proven that despite the high initial investment they require, biotech 
research facilities hold their value well and, in fact, are generally adaptable by second- 
and even third-generation occupants with very little modification necessary. Although 
Forest City did not initially intend to develop a biotech park, biotech firms now occupy 
90 percent of the 700,000 square feet of R&D space offered at the park. 
 
Although the quality of the project and the master plan always have been important 
components of the University Park marketing program, prospective tenants generally 
have not been willing to pay higher rents to acquire them. In fact, some discounts had to 
be offered until the University Common was finished and the master plan could be 
experienced firsthand. The costs associated with the parks and streetscape, as well as the 
significant private investment in infrastructure, have been absorbed into the overall cost 
structure of the project. 
Marketing was accomplished by establishing a relationship with Meredith & Grew, a 
premier Boston brokerage firm. It participated in building planning and is a renowned, 
so anyone looking for space in the Boston region would consult the firm. Thus, Forest 
City did not advertise locally or nationally. Moreover, the hotel has served as a 
marketing tool. 
 
All buildings were preleased prior to start of construction. For example, in Phase III, 
Millennium Pharmaceuticals and Cereon Genomics, the tenants of 45 and 75 Sidney 
Street, approached the developer looking for space with a time deadline. In Phase IV, 
two buildings provided expansion space for Millennium, including one that was its 
corporate headquarters and one building that was expansion space for Alkermes, a 
biotech company that was a startup in the first phase. Millennium occupied about 50 
percent of the total R&D space in University Park and has become a campus within a 
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campus. Thus, many of the tenants in later phases are the result of internal growth of 
early tenants. 
Figure 20. University Part at MIT Project Layout 
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Table 11. University Park at MIT Project Data33 
LAND USE INFORMATION 
Site area (acres/hectares): 27/10.9 
Gross building area, square feet (square meters): 2,300,000 (213,670) 
LAND USES 
Existing Planned Total 
Office net rentable area, square feet (square meters) 702,100 
(65,318) 
681,000 
(63,265) 
1,382,000 
(128,583) 
Retail gross leasable area, square feet (square meters) 92,800 (8,621) 0 92,800 
(8,621) 
Residential units (not including Auburn Court) 142 360 502 
Hotel rooms 210 0 210 
Structured parking spaces 1,550 1,130 2,680 
Floor/area ratio 7.4   
LAND USE PLAN 
Use Acres (Hectares) Percentage of Site 
Buildings 2 (0.8) 7 
Landscaped open space 2.5 (1.0) 9 
Open space 22.5 (9.1) 84 
Total 1.50 (10.9) 100 
BUILDING INFORMATION 
Building Use Size Cost 
Phase I 
1987-1996 
26 Landsdowne Street R&D 100,000 square feet 
(9,290 square meters) 
 
38 Sidney Street R&D 122,000 square feet 
(11,334 square meters) 
 
                                     
 
 
33 Urban Land Institute, 2005 
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64 Sidney Street R&D 126,000 square feet 
(11,705 square meters) 
 
 Total R&D 348,000 square feet 
(32,329 square meters) 
$57,600,000 
Kennedy Biscuit Lofts Residential 142 units $21,200,000 
Auburn Court* Residential   
Phase II 
1996-1998 
350 Massachusetts 
Avenue 
Office 76,400 square feet 
(7,098 square meters) 
 
350 Massachusetts 
Avenue 
Retail 42,600 square feet 
(3,958 square meters) 
 
20 Sidney Street Hotel 210 rooms  
20 Sidney Street Market 50,200 square feet 
(4,664 square meters) 
 
55 Franklin Street Garage 950 spaces  
 Total Phase II  $78,700,000 
Phase III 
1997-1999 
45/75 Sidney Street R&D 276,700 square feet 
(25,705 square meters) 
 
30 Pilgrim Street Garage 600 spaces  
University Park 
Common 
Open space 1.25 acre (0.5 hectare)  
 Total Phase 
III 
 $70,000,000 
Phase IV 
2000-2002 
65 Landsdowne Street R&D 122,400 square feet 
(11,371 square meters) 
$37,500,000 
35 Landsdowne Street R&D 201,300 square feet 
(18,701 square meters) 
$59,400,000 
88 Sidney Street R&D 145,300 square feet 
(13,498 square meters) 
$48,300,000 
40 Landsdowne Street R&D 212,000 square feet 
(19,695 square meters) 
$66,000,000 
80 Landsdowne Street Garage 1,130 spaces $20,800,000 
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91 Sidney Street Residential 135 units $36,200,000 
100 Landsdowne Street Residential 225 units $64,300,000 
Auburn Court, Phase II* Residential 60 units N/a 
Landsdowne Quadrangle Open space 0.5 acre (0.2 hectare) 
 Total, Phase 
IV, estimated 
 $332,500,000 
Phase V 
2002-2003 
23 Sidney Street** In planning   
*Developed by Homeowners Rehab, Inc. (HRI), a not-for-profit developer. Forest City subleased 
this land to HRI for $2,000 per unit. 
**23 Sidney Street is the last University Park parcel to be developed. Its use and building size are 
not yet determined. 
DEVELOPMENT COST INFORMATION 
Total development cost: $560,000,000 
TENANT INFORMATION 
Residential Units 
Area, Square Feet 
(Square Meters) 
Monthly Rent 
Per Unit 
Kennedy Biscuit Lofts 142 692-1,800 (64-167) $1,550-3,100 
Auburn Court 77 670-1,200 (62-111) $1,700-2,600 
Office 
Percent of net rentable area (NRA) occupied: 100 
Number of tenants: 18 
Range of tenant space: 2,000-200,000 square feet (186-18,580 square meters) 
Annual rents: $12-41 per square foot ($129-441 per square meter) 
Average length of lease: 5 to 10 years 
Typical terms of lease: Triple net 
Retail/Entertainment (Major Tenants Only) 
Star Market: 50,200 square feet (4,664 square meters) 
CompUSA: 32,000 square feet (2,973 square meters) 
Austin Grill: 5,800 square feet (539 square meters) 
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Cambridge Trust Bank: 3,400 square feet (316 square meters) 
Espresso Royale Caffe: 1,400 square feet (130 square meters) 
Percent of GLA occupied: 100 
Annual rents: $25-30 per square foot ($269-323 per square meter) 
Average annual sales at Star Market: $434 per square foot ($4,672 per square meter) 
Average length of lease: 10 to 15 years 
DEVELOPMENT SCHEDULE 
Planning started: 1982 
Developer selected: 1983 
Zoning district approved: 1987 
Master plan approved: 1988 
Phase I: 1987-1990 
Phase II: 1996-1998 
Phase III: 1997-1999 
Phase IV: 2000-2002 
Projected project completion: 2003 
 
 
 
In conclusion, there are three critical factors involved in establishing a successful 
biocluster regardless of region. First of all, an initiative from either government or 
educational institutes is necessary to develop a biocluster. For example, Singapore and 
Korea’s bioclusters have been created by strong government will.  
 
Secondly, human resources are essential. Most bioclusters are located adjacent to 
universities or educational institutions and are continually supplied with skilled human 
resources.  
 
A final critical factor is availability of seed and venture capital. Due to the peculiar nater 
of biotechnology as an industry, it takes at least 15 years to produce a product. To 
sustain the long period of business enough capital is essential. The Singapore and Korea 
cases lacked venture capital. Instead, a government agency played a key role through 
regulations and financing. In the U.K, there were a great number of venture capitalists 
and angels investing in biotech.  Most successful bioclusters have been developed by 
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means of these three main factors. 
 
Trends can also be analyzed in the case study. In the U.K, the evolving number of firms 
at the Cambridge cluster has been decreasing since 1999. It doesn’t mean the 
Cambridge cluster’s revenue and size is shrinking, but they have started outsourcing for 
their business line such as manufacturing and sales forces. It could that the intention 
behind outsourcing is to save operating cost and recruit more intelligent scientists and 
market share as a way to enter new markets strategically. 
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V.   YEONGJONG PROJECT 
 
With previous biotechnology market overview and biocluster cases study, this chapter 
will discuss a specific Korea biocluster development, which is “Yeongjong Project”. 
This project case is sponsored by the Federal Development LLC34, who is a master 
developer of the project, so that for their request, this chapter will proposes the optimal 
product and demonstrate the candidate site doable for the biocluster. In additions, by the 
analysis of a real case study, our understanding of biocluster development can be 
enhanced considerably  
 
The Korean local government, IFEZA35, decided to develop 81 acres next to the 
international airport to be a biocluster but they questioned what products should be on 
the site, how big the project should be, and what types of tenants are appropriate for the 
site.  
 
A.  Overview 
1.  Project 
Adjacent to Incheon International Airport, 
which is ranked number one in the world36 
indicated by the orange circle, the 81.6-acres 
project is located on Incheon Yeongjong 
Island, South Korea. It is shown here by the 
blue polygon. It is under IFEZA and its 
master developer is the Federal Development 
LLC who provided the project information 
                                     
 
 
34 Federal Development LLC is a national real estate development firm specializing 
public/private partnership development, based on Washington D.C. Its service includes 
all development procedure such as asset management, marketing, financing, 
development, and construction. 
35 IFEZA (Incheon Free Economic Zone Authority) – The owner of the candidate site 
36 Airport Council International, 2006 
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for this thesis. 
The objectives of the project are as follows: 
 
• Develop a mixed-use commercial and residential complex relating to 
biotechnology industry 
• Build flexible, institutional-quality buildings to support those uses over time 
• Respond to evolving market parameters. 
 
2.   What is IFEZ and Upcoming Projects Surrounding the Candidate Site? 
 
a. IFEZ 
The Incheon Free Economic Zone (IFEZ) consists of three different Incheon city 
districts with a total area of 209 km2 (51,739 acres). Those area are: Songdo (13,162 
acres) , Yeongjong (34,183 acres), and Cheongna (4,394 acres).  Its goal is to 
transform these areas into the logistics, international business, leisure and tourism hub 
of the Northeast Asian region.  The term “Free Economic Zone” applies to the 
development in these three areas with the aim of improving the business environment 
for foreign-invested enterprises and the living conditions for foreigners.  The zone is a 
specially designated area to create the most favorable business and living environment 
where foreign nationals can live and invest freely and conveniently.  Incheon’s Free 
Economic Zone, the first in Korea, was officially designated by the federal government 
in August 2003.  IFEZ is planned to be a self-contained living and business district 
featuring air and sea transportation, a logistics complex, an international business center, 
financial services, residences, schools, hospitals, shopping and entertainment centers. 
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Figure 21. IFEZ Overview37 
 
Songdo International City District began development in 1994 and is being built on 
13,162 acres of reclaimed land. It is a center of diverse international businesses, a hub 
for international trade, an area for knowledge-based technologies, and a place for eco-
friendly urban living.  At build-out in 2020, the population is expected to reach 
252,000. 
 
Yeongjong International City District includes 34,183 acres on the Incheon 
International Airport.  The city will be developed as an eco-friendly airport city by 
2020 with an expected population of 144,800 persons.  It will be a functional city with 
residential amenities for airport staff and visitors, as well as logistics, commercial and 
distribution facilities.  Yeongjong will provide an optimal environment for logistic, 
tourism and leisure in conjunction with the Incheon International Airport. 
 
The Cheongna District, on the mainland adjacent Yeongjong Island, will focus on 
entertainment and will feature a world-class theme park.  The 4,394-acre district is a 
residential area with sports facilities, a floriculture complex, and a business area 
specially designed for international finance.  By the end of 2008 the population is 
expected to reach 90,000 persons. 
                                     
 
 
37 Incheon Free Economic Zone Authority (IFEZA) 
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The following section specifically discusses the Yeongjong island projects where our 
candidate site is located. The candidate site represents the triangle on the map.  Besides 
our project, it also discusses ongoing and upcoming projects on the island to get a sense 
of the environment and effects around the candidate sites.  Based on the surrounding 
infrastructure for biotechnology, the environment, and the regulations of the Yeongjong 
Island, the author proposes appropriate product types and a plan for biotechnology are 
proposed. 
 
b. Yeongjong Island developments in progress 
There are six major developments in progress in the island. They include the Youngyu, 
Muui Tourist Complex project, and the Unbuk Multi-Leisure Complex project. The goal 
is to create environmentally sustainable urban environment and improve settlement 
condition for foreigners by providing world class hospitality (educational, medical, and 
residential facilities) and coastal entertainments areas.  The goal of the four projects is 
an international hub of logistics with an advanced airport and harbor.   
 
 
Infrastructure development is also in progress.  The length of Incheon Bridge is 21.48 
km (13.35 miles) and connects Incheon International Airport with Songdo International 
City, No. 2, 3 Seoul-Incheon Highway, and the Seoul Outer Circulation Road.  
Construction of the Incheon Bridge allows residents on Yeongjong Island to connect and 
communicate easily and directly with Songdo and Seoul City.  It also secures 
competitiveness for logistics collection and delivery at the airport, harbor, and industrial 
zone.  Figure 22 shows the location, size, construction period, and developer of each 
project on the island. 
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Figure 22. Projects in progress on Yeongjong Island38 
 
 
 
B.  Geographical Information, Infrastructure, Tax Zone and Government 
Support of IFEZ 
 
1.  Geographical Information 
IFEZ is the right place to cover the East Asia market geographically. IFEZ is 
strategically situated between the world’s largest market, China, Japan, and Russia. 
People can fly to Beijing, Shanghai, Tokyo, and Vladivostok within two hours and even 
Hong Kong within three hours. See Figure 23. The Seoul-Incheon metropolitan area has 
a population of 23 million. 
                                     
 
 
38 IFEZA 
Candidate Site 
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Figure 23. IFEZ Market Overview 
 
 
2.   Infrastructure of IFEZ; Incheon Airport and Harbor 
According to Airport Council International39, Incheon Airport is ranked No 1 in the 
world for airport service.  It currently serves 59 airlines, with routes to 133 cities in 41 
countries and is the largest transshipment rate in Asia and the Pacific. The size of the 
cargo terminal is 270 acres and is expanding by an additional 261 acres. Incheon 
International Port is a port having sea and air multi modal network with Incheon 
International Airport.  It has currently 78 ship berths, to be expanded to 135 berths by 
2011. 
3.  Tax Zone 
Foreign investment takes advantage of significant tax benefits and tax incentives in the 
area.  Since the candidate site is located in the FEZ, the corporation tax and corporate 
income tax is exempt at 100% for the first 3 years and levied at 50% in the following 2 
years. In addition, local taxes such as acquisition, registration, and property taxes are 
                                     
 
 
39 Air Cargo: Worlds No. 3, Passenger: World’s No. 10 
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exempted 100% for the first 10 years.  Detailed information of the tax zone is shown in 
Table 12. 
 
Table 12. IFEZ Tax Zone Information 
Beneficiary Tax Incentives Requirements(Amount of Investment)
Tariff 100% for 3 years Imported capital goods
National
tax
Local tax
Logistics: More than USD 5 million
Manufacturing: Over USD 10 million
Tourism: More than USD 10 million
Type of Tax
Corporation Tax and
Corporate Income Tax
Acquisition Tax,
Registration Tax,
and Property Tax
10 years: 100% Following
3 years: 50%
3 years: 100% of Following
2 years: 50%Foreign Investment
Companies located
in the FEZ
 
 
Manufacturing companies with more than $ 10 million USD of foreign investment, 
logistic companies with more than $5 million USD of foreign investment will be 
exempt corporate tax, income tax, acquisition tax, registration tax, and property tax for 
3 years, and reduce them by 50% for subsequent 2 years. 
 
 
4.  Government Support 
There are three types of administrative supports. First, in terms of the financial 
environment, the government allows direct payment of costs arising from current 
transactions within the range of $10,000 USD. The main currencies including the dollar, 
Euro, and Yen will be used freely.   
 
Second, the government provides guidance on zoning issues, investment, and starting a 
business. Specifically, the IFEZ authority will provide integrated and end-to-end support 
for administrative supports required for the various permissions/licenses issued by local 
governments.   
 
Third, there is an ombudsman available to deal with business and personal disputes 
involving foreign firms. A branch of the central arbitration authority is also available for 
facilitating commercial dispute resolutions. 
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C.  Biocluster Business Environment surrounding IFEZ 
The R&D and manufacturing infrastructure of the biocluster at Incheon are well 
equipped compared to other territories, even though the number of companies and their 
revenue is low.  Three colleges at Incheon are highly focused on the R&D related to 
bio industry and Incheon Bio Industry Center (“IBIC”), founded by the City of Incheon 
supports the R&D operation of each firms and generates substantial human resources. 
This environment provides a good infrastructure for biotechnology in Incheon 
compared to other regions in Korea. 
 
Korea Biotechnology Commercialization Center is a consignment manufacturing 
facility for the public and the Korea Environment & Merchandise Testing Institute, 
which conduct all clinical animal trials under the international standard. It also conducts 
the toxicity tests of new chemicals, agrichemicals, and medicines.  Inha University’s 
College of Medicine and Gachon University of Medicine and Science have also built a 
clinical trial center fitting to international standards. Finally, Celltrion and TS 
Corporation’s R&D center lead the biotechnology industry within the Incheon area. 
 
Following examples are facilities surrounding the candidate site. In this section, the 
author identifies optimal product types for the candidate site in terms of taking 
advantage of these facilities efficiently and achieving synergy through them.  
 
 
1.  Public R&D Centers 
 
There are three universities at Incheon, University of Incheon, Inha University, and 
Gachon University of Medicine and Science. They offer 17 biotechnology industry- 
related academic programs including biology, life science, and chemistry.  There are 
also 30 research centers within each university that work on biotechnology basic and 
applied research. Table 13 shows the program examples of each university. 
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Table 13. IFEZ Public R&D Information 
University Programs 
University of Incheon Chemistry, Biology, Materials Science & 
Engineering 
Inha University Chemical Engineering, Biology, Textile 
Materials Science & Engineering, 
Chemistry, Life Science, Marine Science 
& Engineering, Food & Nutrition, Medical 
Science 
Gachon University of Medicine and 
Science 
Life Science, Food & Nutrition, Public 
Health & Environment System Science, 
Medicine & Science 
 
2.  Korea Biotechnology Commercialization Center  
Korea Biotechnology Commercialization Center (“KBCC”) in Songdo New City is a 
growing contract manufacturing organization with a state-of-the-art bio-manufacturing 
facility that complies with the latest U.S. and EU current Good Manufacturing Practices 
(“cGMP”) Regulations and Guidelines. KBCC is dedicated to meeting client 
manufacturing needs for the production of genetically engineered proteins and 
monoclonal antibody therapeutics.  The four acre center has a cGMP plant capable of 
500 liter fermentation and 500 liter for animal cell culture. 
 
KBSS offers a wide range of bio-manufacturing services that include Active 
Pharmaceutical Ingredient (API) and biopharmaceuticals manufacturing.  Its main 
services are contract manufacturing service such as API manufacturing, clinical trial 
sample and therapeutics manufacturing, pre-clinical and testing sample manufacturing, 
contract testing service, contract process development, and research assistance. 
 
3.  Incheon Bioindustry Supporting Center, Songdo Techno Park 
IBIC systemizes the use and management of public equipment owned by IBIC.  Also 
IBIC supports small and medium and venture firms that lack an R&D infrastructure. 
These types of companies are able to use IBIC’s equipment and strengthen the 
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manufacturing operation and their R&D capacity. There is an analysis lab (refining and 
analysis) and a cultivation lab in the Get-Pearl Tower.  In addition, IBIC maximize the 
synergy with the Korea Biotechnology Commercialization Center by taking advantage 
of the sterilization machine and culture medium. 
 
4.  Clinical Trial Center, Inha University Hospital 
In 2006, the Inha University College of Medicine established a clinical trial center. The 
center operates scientific and ethical clinical trials under the Korea Guideline for Good 
Clinical Practice (“KGCP”) and the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceutical for Human use by Korea 
Food and Drug Administration (“KFDA”) and the Good Clinical Practice (“GCP”) by 
the U.S. Food and Drug Administration.  It obtains the clinical trial expertise from 
University of Washington Hospital, which expands the number of professionals and 
helps accumulate clinical research experience, which is essential to becoming a 
globalized clinical research institute. 
 
5.  Celltrion, Biophamaceutical Company 
Celltrion is a leading biopharmaceutical company dedicated to providing high quality 
services to accelerate product development and manufacturing capabilities for clients 
and business partners focused on the treatment and prevention of human diseases.  
Celltrion is a joint venture between a group of Korean investors and VaxGen to provide 
manufacturing solutions for the large-scale production of mammalian cell culture 
derived biologics.  Celltrion is now evolving into a fully integrated biopharmaceutical 
company through the development of biologics via in-licensing and co-development 
relationships. 
Celltrion’s 23-acres facility is in the center of the high-tech park in Songdo New City in 
IFEZ.  Construction of Celltrion’s 50,000 liter capacity biopharmaceutical 
manufacturing facility is underway in the Songdo New City.  It is expandable to 
150,000 liters based on client demand.  This facility is designed to comply with the 
cGMP Standards of the U.S. Food and Drug Administration. 
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6.  TS Corporation R&D Center 
TS Corporation is one of the leading food companies in the field of sugar, food, 
agriculture business, and animal feed. It is expanding its vision to include biotechnology 
and genetic engineering. TS Corporation’s R&D center is focused on developing animal 
cell biotechnology by 2010. The center will be a leader of biotechnology and 
nanotechnology, having already developed a significant compound for the treatment 
anemia called Aropotin40  
 
7.  Plans in Progress for Biotechnology, Driven by Incheon Government 
The four plans here represent the potential development opportunity and could 
contribute to the Yeongjong Island cluster, which becomes more efficient and 
productive by establishing better infrastructure connecting to these clusters for synergy. 
 
a. Establishing the East Asia Bio-Medical Hub (“EABMH”) at 
Songdo 
East Asia Bio-Medical Hub is a 611-acres project that consists of seven R&D Centers 
and four bio medical and biotechnology clusters. The components of the R&D centers 
are: Well-Being Center, Therapy Center, Fusion of Eastern and Western Medicine 
Center, Pharmaceutical Center, East-Asia Gene Center, and Revival Medical Center. 
The four clusters consist of Medical Tour, Customized Pharmacy, High-Technology 
Medical Equipment, and Transplantation Medical. The medical hub is planned for 
maximizing synergy among each center and cluster by putting star scientists at the each 
center and cluster. 
b. IFEZ Science Center 
In May 2007, the mayor of Incheon City and Dean Lewis, CEO of Science Center41 in 
                                     
 
 
40 Medical cure of anemia 
41 The Science Center started in 1963, Philadelphia and is the first, and one of the 
largest, urban research and technology park in the world. Throughout its 45 year history, 
the Science Center’s reach and influence has increased significantly with 2 mil square 
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Philadelphia agreed to a MOU (Memorandum of Understanding) regarding an 
establishment and operation of Incubation Center in IFEZ. 
 
 
c. Gachon University Gil Hospital, Clinical Research Center 
This clinical research center develops new biomedicines for export to the European 
market.  Gachon University Gil Hospital signed a MOU with Charite Hospital, an 
affiliatied hospital of Germany’s Humboldt University’s College of Medicine, to 
organize an association clinical research center to obtain a clinical trial system within a 
developed country. 
 
 
d. Cheongna B-port Project 
This 148-acres project is affiliated with Seoul National University and KIST, which is 
the most popular technology university in Korea. 
 
As mentioned earlier, educational institutions and government involvement around the 
cluster is important to the cluster’s success. In Incheon, especially IFEZ, the 
biotechnology R&D centers, hospital, and government support center for establishing 
business in the area provides either local or international biotechnology players with a 
fewer errors, cost, and more productive business. In addition, several mega-biotech 
related developments in progress justify the site as a good environment for biocluster. 
 
 
 
 
 
 
 
                                                                                                           
 
 
feet of research space, the creation of more than 26,000 jobs, and the raising of more 
than $150 million (USD) in government and venture funding 
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D.  Proposed Business Plan for Pharmaceutical Manufacturing Facilities 
The author proposes that pharmaceutical manufacturing facilities would be the best 
product type on the candidate site for the following reasons. 
 
1. Reasons Why Pharmaceutical Manufacturing Facilities is the 
Optimal Product for the Candidate Site 
 
1) Market, shift in the industry’s focus and investment priorities 
Emerging markets in Asia (excluding Japan) were the biggest drivers of global 
growth. Pharmaceutical industry is also one of them. According to IMS Health42, 
sales in Asia-Pacific (excluding Japan) and Africa advanced 10.5% to 56.1 
billion (audited) in the 12 months through June 2007. China, among the world’s 
top 10 markets, experienced an increase of 15.9% in pharmaceutical sales to 
$12.0 billion, and the Korean market increases by 23.5%. Because they are 
experiencing double-digit growth, countries such as China, Korea, and Russia 
are gaining ground in the global pharmaceutical market. IMS Health expects this 
momentum to continue, which will force important shifts in the industry’s focus 
and investment priorities.  
 
 
2) Government Support: Tax benefit, Administration 
The 100% income tax redemption for the first three years, 50% for next two 
years, and 100% local tax for the first 10 years are remarkable incentives. 
Furthermore, government is willing to provide support with finance and 
administration so the company could set up more effectively.  
 
 
 
                                     
 
 
42 IMS is the provider of business intelligence and strategic consulting services for the 
pharmaceutical and healthcare industries. 
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3) Great geographical advantages 
 
Adjacent to the Incheon international airport, and the international harbor, it 
takes minimal time for the site to import and export a manufactured and finished 
product. In addition, because the site is close to the airport (10 minutes by car), 
management and staff are able to reach the site and communicate with the local 
manufacturing facility efficiently and easily. 
 
4) Security 
According to William B. Wiederseim (PharmaBioSource, May 2003), in a recent 
survey of 14 parenteral site acquisition candidates, my client rejected the best 
candidate because the site could not be secured. Providing a safe and secure 
work environment is a critical determinant for a candidate site in terms of 
physical security measures, administrative controls, and personal ownership. 
The Korean government including Incheon introduced the Alien Land 
Acquisition Act in 1998 for equal ownership for foreigners. In addition, IFEZA, 
which controls the area, cooperates on facility design, building modifications, or 
physical security improvements.  
 
 
5) Right Location for a Pharmaceutical Manufacturing Facility 
The candidate location is surrounded by mountains and sea and is away from the 
residential area. This is an important matter since manufacturing facilities 
needed to be sensitive to distances to the residential area because of the 
hazardous wastes.  
 
 
6) Substantial human resources 
According to Korea Science Foundation’s forecasting43, the demand of PhD or 
Post-PhD of biotechnology is 1,275 but the supply is 2,681 so there is a 52.4% 
                                     
 
 
43 Korea Science Foundation, Forecasting of R&D human resource, 2000 
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surplus over demand during 2000 to 2010. In addition, there are high-performing 
educational institutions around the candidate site. 
 
 
7) Good Environment for Pharmaceutical Manufacturing Facilities 
Adjacent to the candidate site, there are universities dedicated to biotechnology, 
Korea Biotechnology Commercialization Center supporting cGMP, Clinical 
Research Center helping clinical trials research, and various other organizations 
that help international firms set up more efficiently. In addition, a world leading 
pharmaceutical company, Celltrion is evidence that the candidate site area is an 
excellent environment for a pharmaceutical manufacturing facility. 
 
 
8) Cost cutting  
Globally, pharmaceutical companies are searching for ways to reinvigorate 
growth and grapple with assorted risks. In addition to dealing with 
biotechnology firms, they are employing new tools to improve their R&D 
efficiency and searching geographically to save operating cost in manufacturing 
facilities. Under the circumstances, the IFEZ offers relatively low labor cost but 
similar qualified labor to cut overall operating costs. In addition, tax benefits and 
lower delivery cost play a role in improving the financial situation. 
 
 
9) Opportunity to Enter the Asia Market 
Setting up a pharmaceutical manufacturing facility in Asia, especially in Korea 
is an opportunity to acquire more local information such as market conditions, 
political issues, even newest technologies developed locally since the Asian 
market grows the fastest and is a one of the major markets. 
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10) Patent Safety 
China, India, and other developing countries in Asia have been particularly 
notorious for ignoring foreign companies’ patents 44 . However, Korea has 
already set up the environment and law to protect international patents. 
 
 
11) Friendly Environment for Foreigners 
IFEZ area consisting of Songdo New City, Yeongjong, and Cheongna is well 
known to foreigners. Every year, number of foreigners is increasing more and 
more that means friendlier environment to foreigners is establishing for their 
needs. Near the candidate site, there are already 1,881 households sold to 
foreigners and 2,877 households leased by foreigners. In addition, near 
Yeongjong Island, Cheongna district provides with entertainment and a world-
class theme park. 
 
 
2. Characteristics of Pharmaceutical Manufacturing Facilities 
 
Pharmaceutical manufacturing facilities are charged with meeting two significant 
objectives: performance and conformance. Facilities deliver increasingly complex and 
valuable products configured in evolving, technically complicated dosage forms and 
therapies.  Facilities must also comply with ever-changing and demanding regulatory 
regimes within the world’s statutory bodies.  These are two fundamental challenges 
faced by facility professional’s whose keen appreciation of the dynamic forces shaping 
the industry and prudent facility designs contribute to the enterprise’s strategic long-
term viability. 
 
 
 
 
                                     
 
 
44 Standard & Poor’s Industry Survey report, 2007. 
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Figure 24. Typical Pharmaceutical Manufacturing Facility Cost profile 
 
Delivering modern pharmaceutical manufacturing facilities typically takes between six 
months and three years, and can cost hundreds of millions of dollars when considering 
the building, facilities, complicated equipment, and sub-systems necessary to achieve 
the intended production output and quality. Figure 24 shows the cost profile when 
building pharmaceutical manufacturing facilities. Mechanical occupies the highest 
portion of total cost and then civil/structural cost.  
 
Outside technical consultants are increasingly deployed in response to demands for 
expertise in certification validation, high purity materials, process application, and 
automation.  Facilities professionals are challenged with the integration of many 
delivery options.  Timing and budgeting processes for new facilities are complicated 
by issues flowing from partners and alliances, as well as market entry dates dependent 
on R&D and regulatory approvals.  Anticipating launch dates and production 
requirements for sample production and market entry has an impact on capital 
deployment. 
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a. Current Good Manufacturing Practices (cGMP)45 
The need to meet the current Good Manufacturing Practices regulations is paramount in 
the pharmaceutical industry especially when expanding to international business even 
though cGMP is a U.S. FDA’s regulation.  Facilities that effectively incorporate the 
GMP requirements are easily licensed and thus bring the project to market in a timely 
fashion.  The corporation of the GMP requirements into Good Design Practices 
(“GDP”) at the onset of the project ensures that this aspect of regulatory requirements is 
met.  Facility designs that do not adequately or that poorly address cGMP requirements, 
face more regulatory scrutiny and possibly will not be licensed without significant 
changes.  
 
From a real estate perspective, cGMP and GDP are critical factors for a facility to meet 
an international standard when building a pharmaceutical facility. Therefore, the author 
reviews and selects some of the regulations be considered importantly, especially the 
FDA’s 21 CFR46 Part 211 subparts C and D to ascertain the agency’s requirements and 
expectations in real estate design issues. 
 
211.42 Design and construction features 
a) Any building or buildings used in the manufacture, processing, packing, or 
holding of a drug product shall be of suitable size, construction, and location to 
facilitate cleaning, maintenance, and proper operations 
b) Any such building shall have adequate space for the orderly placement of 
equipment and materials to prevent mixups between different components, drug 
product containers, closures, labeling, in-process materials, or drug products, 
and to prevent contamination. The flow of components, drug product containers, 
closures, labeling, in-process materials, and drug products through the building 
or building shall be designed to pre vent contamination. 
                                     
 
 
45 The reason of small “c” in cGMP: the FDA tells a manufacturer what must be done, 
but not how to do it. This fact has led to a variety of interpretive solutions to achieve the 
desired result relative to facility design. Utilizing this approach enables technologies to 
develop that can more effectively achieve the desired goals and objectives set forth by 
the agency. 
46 Code of Federal Register (CFR) issued by FDA 
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c) Operations shall be performed within specifically defined areas of adequate size. 
There shall be separate or defined area for the firm’s operations to prevent 
contamination or mixups. 
d) Operations relating to the manufacture, processing, and packing of penicillin 
shall be performed in facilities separate from those used for other drug products 
for human use. 
 
 
211.44 Lighting 
Adequate lighting shall be provided in all areas. 
 
 
211.46 Ventilation, Air filtration, Air heating and Cooling 
a) Adequate ventilation shall be provided 
b) Equipment for adequate control over air pressure, micro-organisms, dust, 
humidity, and temperature shall be provided when appropriate for the 
manufacture, processing, packing, or holding of a drug product. 
c) Air filtration systems, including prefilters and particulate matter air filters, shall 
be used when appropriate on air supplies to production areas. If air is 
recirculated to production areas, measures shall be taken to control recirculation 
of dust from production. In areas where air contamination occurs during 
production, there shall be adequate exhaust systems or other systems adequate to 
control contaminants. 
d) Air-handling systems for the manufacture, processing, and packing of penicillin 
shall be completely separate from those for other drug products for human use. 
 
211.63 Equipment design, size, and location 
Equipment used in the manufacture, processing, packing, or holding of a drug product 
shall be of appropriate design, adequate size, and suitably located to facilitate operations 
for its intended use and for its cleaning and maintenance. 
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211.65 Equipment construction 
a) Equipment shall be constructed so that surfaces that contact components, in 
process materials, or drug products shall not be reactive, additive, or absorptive 
so as to alter the safety, identity, strength, quality, or purity of the drug product 
beyond the official or other established requirements. 
b) Any substances required for operation, such as lubricants or coolants, shall not 
come into contact with components, drug product containers, closures, in-
process materials, or drug products so as to alter the safety, identity, strength, 
quality, or purity of the drug product beyond the official or other established 
requirements. 
 
b. Validation 
An important regulatory issue affecting of a pharmaceutical facility is validation.  The 
FDA requires that all processes producing drug substances be validated.  The FDA’s 
definition for process validation, as stated in the Guideline on General Principals for 
Validation is: 
 
Establishing documented evidence which provides a high degree of assurance 
that a specific process will consistently produce a product meeting its 
predetermined specifications and quality attributes. 
 
This statement not only requires that manufacturing processes be validated, but the 
facility systems that support production as well.  For example, an aseptic processing 
operation requires a “clean” room. Consequently, the heating, ventilating, and air-
conditioning system must be validated in order to ensure that the process is truly aseptic.  
Furthermore, all critical utility systems (e.g. water, steam, compressed air) need to be 
tested to ensure proper operation. 
 
Figure 25 shows a project cycle that explains the timing of validation, FDA, and CFR 
approval. During the design/construction of the facilities, developers should consider 
the project cycle so that effective collaboration specialty construction contractors and 
managers is possible.  
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Figure 25. Typical Project Cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Site Survey of the Candidate Site 
 
The author visited the site for the site survey to observe physical conditions. It is away 
from residential areas and surrounding low mountains. Accessibility is limited and there 
is no direct road from the highway abutting the site. In addition, all roads to the site are 
off-road. The upper right illustration shows the upper side of the map which depicts 
wildland. The middle illustration shows the condition of the road divided into two parts 
and it appears that there is a bridge since there is a small pond under the road. In figure 
26, the lower right illustration shows the lower side of the left map and there appears to 
be an agricultural area. However, there is an IFEZA sign from 2007 describing a 
restriction of any usage of the land. Overall, the topography of the candidate site is flat. 
 
 
 
 
 
 
 
 
Ideas R&D Manufacturing Distribution Marketing Consumers 
Plan Design Build Operate
Validation
FDA 
CFR
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Figure 26. Candidate Site Features 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 shows the environment around the candidate site regarding medical, 
educational facilities, entertainment facilities and residential areas. Across the 10 lane 
Incheon Airport Highway from the candidate site, there is a residential area. Some 1,881 
households were sold to foreigners and 2,877 households leased by foreigners.   
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Figure 27. Environment of the Candidate Site 
 
 
 
 
4. Case Study for Design as the Candidate Site 
 
AstraZeneca’s site has similar physical conditions and government support as the 
candidate site. With similar size, geographic conditions and government initiatives for 
the development, the AstraZeneca’s headquarters will provides a sense of the post 
development environment of the candidate site. 
 
AstraZeneca in Delaware is a global healthcare, pharmaceutical company committed to 
enhancing patient health. It has more than 66,000 employees’ worldwide. 
 
 
 
Incheon Airport Highway 
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Figure 28. View of the AstraZeneca Site 
Figure 28 is an overview of 
the AstraZeneca Site from the 
sky. The red circle is 
approximately 86 acres, which 
is similar in size as the 81-
acres candidate site. It is also 
divided into two sections by 
the highway, but the site is 
connected by a sky bridge as 
illustrated in Figure 29. 
 
 
 
 
 
 
 
 
 
Figure 29. View of the Sky Bridge 
Figure 29 shows how to connect two 
sections.   
 
 
 
 
This list indicates the conditions State of Delaware offered AstraZeneca 
• State, County, or local tax incentives; 
• Community support by business, education, scientific, and non-profit leaders; 
• Support by top political leaders to maintain the economic vitality of a location; 
and 
• Quality of life for employees such as distance to work, education, adequate 
housing, cost of living, and good roads/traffic, etc. 
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Tax incentives and government support was considered a key component of the project.  
The General Assembly introduced and passed legislation, and the governor signed it 
into law – in just 10 days.  Since other states have taken as long as 3 years to pass 
similar legislation, this was a clear statement to AstraZeneca of the responsiveness of 
“smarter, quicker, more flexible” Delaware. It is true that Delaware offered enough 
incentives to attract pharmaceutical firms but the incentives were, in fact, fewer than 
those of IFEZA’s 
 
 
5. Potential Tenants for the Candidate Site 
 
As mentioned in Chapter Ⅲ, Biotechnology Market and Trend, 66% of U.S. biotech 
companies and 76% of European Biotech companies plan to expand operations globally. 
One of the business lines is contract manufacturing. Both European and U.S. global 
pharmaceutical companies currently contract for manufacturing around 66% but they 
plans to increase up to 76% from 66%. It is clear that many global pharmaceutical firms 
want to set up their manufacturing facilities overseas.  
 
The author looked at the top the pharmaceutical firms’ pipelines to find out specific 
tenants as shown in Table 14. New drug pipelines require new manufacturing systems 
and facilities. In addition, new drugs should be manufactured at efficient and innovative 
facilities in terms of saving cost savings and safety.  
 
As mentioned earlier, it is reasonable to look at top global firms’ pipelines in order to 
find potential tenants since global companies plan to go overseas. However, company 
lists might not be directly related to real results since there is a lack of industrial survey 
and interview results with representatives of the firm. 
 
As shown in a Singapore case, since Abbott, Merck &Co, Phizer, and Wyeth already 
went to the Asia market, Bristol, Johnson & Johnson, Eli Lilly & Co, and Schering-
Plough having a red circle of the lists would be the target tenant.  
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Table 14. Top Pharmaceutical Companies New Product Pipeline47 
Company Name of Product Treatment Status
EST 2012 
Sales($ Mil)
Bristol-Myers 
Squibb Co. Saxagliptin Diabetes Phase III 620
Ixempra Cancer Approved 850
Apixaban Thrombosis Phase III 350
Belatacept
Immuno-
suppression
transplants Phase III 300
Ipilimumab Cancer Phase III 250
Abbott Laboratories Vicodin CR Pain Filed 400
ABT-335
Cholesterol and
tryglycerides 
regulation Filed 150
ABT-874 Psoriasis Phase III 600
Johnson & Johnson CNTO 1275 Psoriasis Filed 1100
Paliperidone palmitate Schizophrenia Filed 950
Ceftobiprole Bacterial infections Filed 600
Dapoxetine Premature ejaculatioFiled 400
Tapentadol IR Pain Filed 350
Xarelto Thrombosis Phase III 500
CNTO-148 (partnered 
with
Schering-Plough) Rheumatoid arthritisPhase III 850
Eli Lilly & Co. Effient
Acute coronary 
syndrome Filed 450
Zyprexa Adhera
(olanzapine depot) Psychosis Filed 500
Arzoxifene Osteoporosis Phase III 350
Byetta LAR Diabetes Phase III 380
Enzastaurin Cancer Phase III 180
Merck & Co. Cordaptive
Cholesterol 
regulation Filed 300
MK-0524B
Cholesterol 
regulation Phase III 400
MK-0974 Migraine Phase III 800
MK-0364 Incontinence Phase III 100
Deforolimus (MK-8669)Cancer Phase III 30
MK-0759 Pain Phase II 80
Pfizer Inc. Zeven Skin infections Approvable 400
Axinitib Cancer Phase III 410
Fesoterodine Incontinence
Approved in
Europe 500
CP-675 Skin cancer Phase III 550
Apixaban (partnered 
with
Bristol-Myers Squibb) Thrombosis Phase III 350
CP-751 Cancer Phase III 200
Schering-Plough
Golimumab CNTO-148
(partnered with
Johnson & Johnson) Rheumatoid arthritisPhase III 850
Sugammadex Novel anesthetic Filed 800
TRA Acute coronary syndPhase III 375
Bocepravir Hepatitis C Phase III 400
Asenipine Schizophrenia Filed 150
Org 36286 Infertility Phase III 200
Wyeth Relistor Constipation Filed 400
Pristiq Depression Approved 200
Pristiq Vasomotor symptomApprovable 300
Viviant Osteoporosis Approvable 150
Aprela Osteoporosis & menPhase III 200
Bapineuzumab Alzheimer’s Phase II 550  
                                     
 
 
47 Standard & Poor’s: Industry Surveys Healthcare (Pharmaceuticals, 2008) 
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VI.   CONCLUSION 
 
The biotechnology industry, which started with small U.S. pioneering companies in 
1970s, is a global industry.  Today, more attention is placed on this industry than any 
other industry.  Many developing countries such as Singapore, Korea, and China, and 
even developed countries, such as the United States and the European Union have 
designated the industry as a driver of their economies and have started and to heavily 
invest in the industry. 
 
Because of this trend, real estate developers should pay attention to this unique 
opportunity.  With the economic growth in the 1980s in the U.S., developers would do 
well to recall the high demand in the office space and office centers.  This author 
believes that the real estate demand of the biotechnology industry is the same as the 
office market demand in the U.S. in the 1980s.  Along with high growth and 
investment in the biotechnology industry, the demand for offices where people can work, 
laboratory space to sustain the biotech business, space where people can research and 
develop products, and related facilities such as housing, and manufacturing plants 
should also increase.  However, most real estate developers are unfamiliar with biotech 
real estate and the unique design and demand requirements for of the facilities. 
 
This thesis is for those developers who need assistance in understanding the 
biotechnology industry and assistance in determining the global need and this 
opportunity that biotechnology offers.  
 
From the case study of the Yeongjong Project, developed by the Federal Development 
LLC, the author conveys an understanding of the Korean biotech market and methods to 
find the right opportunity.   
 
To find the right development opportunity, developers should recognize that the biotech 
trend involves global pharmaceutical firms that seek global strategic locations for 
expanding market occupancy, saving operation costs, finding secured locations for 
business, and substantial human resources.  The Yeongjong Project provides global 
pharmaceutical firms with all these reasons to set up business. The region is calling.   
 
For a comparison, Singapore is aggressively promoting and developing its 
biotechnology industry. Hundreds of millions of dollars were invested into the sector to 
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build up infrastructure, fund research and development and to recruit top international 
scientists to Singapore. As a result, leading drug makers, such as GlaxoSmithKline, 
Pfizer, and Merck & Co., have set up plants in Singapore. Pharmaceuticals now account 
for more than 16% of the country’s manufacturing production. The industry is now an 
engine of Singapore’s economy. Korean government also pursues opportunities to 
develop its biotechnology industry.  In addition, Korea has a good environment for 
global biotech firms to establish themselves and draw others into the area.   
 
The author believes that Korea is the right location for those biotech companies that 
seek new locations for expanding business globally or entering this new market. 
Moreover, Yeongjong Project will be a successful for pharmaceutical manufacturing 
facilities and create demonstration effects to other global pharmaceutical firms to 
follow so that Korea will become a hub of pharmaceutical industry in Asia. 
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